Adam J. Gordon
No Rating Available
(Learn About Our Rating System)

Adam J. Gordon, MD, MPH, FACP, DFASAM

Languages spoken: English

Adam J. Gordon's professional mission is to improve the access and quality of care of patients who have vulnerabilities, including those with addiction disorders. He is the Elbert F. and Marie Christensen Endowed Research Professor, tenured Professor of Medicine and Psychiatry at the University of Utah School of Medicine, and the Section Chief of Addiction Medicine at the VA Salt Lake City Health Care System. He is a board-certified internal medicine and addiction medicine physician and is a Fellow in the American College of Physicians (FACP) and a Distinguished Fellow in the American Society of Addiction Medicine (DFASAM). He is the PI of the Greater Intermountain Node (GIN), a Center site of the NIH NIDA Clinical Trials Network; founded and is the Director of the Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA); and founded and is the Emeritus Director the Vulnerable Veteran Innovative Patient-Aligned-Care-Team (VIP) Initiative, a clinical-evaluation initiative at the VA Salt Lake City Health Care System. Adam J. Gordon is a Core Faculty member of the VA Salt Lake City Informatics, Decision-Enhancement and Analytic Sciences (IDEAS) Center, a Department of Veterans Affairs Health Services Research and Development (HSR&D) Center of Innovation (COIN). He is also the Editor-in-Chief of the journal Substance Abuse (impact factor 3.9).

Adam J. Gordon has a 25-year track record of conducting research on the quality, equity, and efficiency of health care for vulnerable populations, including those who are homeless and those with substance use disorders. A major theme of his research includes examining the efficacy, effectiveness, and implementation of evidence-based identification, assessment, and treatments for patients with addiction. His methodological skills include health services, clinical trial, large database, and implementation science research. He has received efforts on over 100 federal peer reviewed grants from the NIH, VA, AHRQ, PCORI, and SAMHSA. He has authored over 310 peer reviewed articles (15.3% first authored, 27.2% senior authored, 40.8% authored with mentee) in high impact journals (e.g., JAMA, BMJ, Lancet; H-index=56) and presented/published hundreds of scholarly works. As evidence of how his research has impacted clinical care and my profession, he was awarded one of VA HSR&D’s highest honors by receipt of the 2021 VA Health Services Research and Development (HSR&D) “Health System Impact Award” and received the 2022 David C. Lewis, MD Service to Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) Award.

He has mentored undergraduate, graduate, MD, and PhD trainees, VA and K- Career Development Awardees, and junior through tenured faculty. In addition, his post-doctoral mentees have received research Career Development Awards and have obtained large research awards. He is a primary or secondary mentor on over a dozen current or prior VA, NIH K-, or institutional K-awards. He has been honored locally and nationally for his mentorship abilities: named as an inaugural VA Health Services Research and Development National Mentor Network (MNet) mentor, received the “Allen Humphrey Excellence in Medical Student Research Mentoring Award” from the University of Pittsburgh School of Medicine, and was the recipient of the 2013 W. Anderson Spickard, Jr. Excellence in Mentorship Award from Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA). His time allocation (for a 60-hour work week between the University and the VA is 80% research/mentoring, 10% clinical/education, 10% administration).

Specialties

Board Certification

American Board of Addiction Medicine
American Board of Internal Medicine
American Board of Preventive Medicine (Addiction Medicine)

Adam J. Gordon's professional mission is to improve the access and quality of care of patients who have vulnerabilities, including those with addiction disorders. He is the Elbert F. and Marie Christensen Endowed Research Professor, tenured Professor of Medicine and Psychiatry at the University of Utah School of Medicine, and the Section Chief of Addiction Medicine at the VA Salt Lake City Health Care System. He is a board-certified internal medicine and addiction medicine physician and is a Fellow in the American College of Physicians (FACP) and a Distinguished Fellow in the American Society of Addiction Medicine (DFASAM). He is the PI of the Greater Intermountain Node (GIN), a Center site of the NIH NIDA Clinical Trials Network; founded and is the Director of the Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA); and founded and is the Emeritus Director the Vulnerable Veteran Innovative Patient-Aligned-Care-Team (VIP) Initiative, a clinical-evaluation initiative at the VA Salt Lake City Health Care System. Adam J. Gordon is a Core Faculty member of the VA Salt Lake City Informatics, Decision-Enhancement and Analytic Sciences (IDEAS) Center, a Department of Veterans Affairs Health Services Research and Development (HSR&D) Center of Innovation (COIN). He is also the Editor-in-Chief of the journal Substance Abuse (impact factor 3.9).

Adam J. Gordon has a 25-year track record of conducting research on the quality, equity, and efficiency of health care for vulnerable populations, including those who are homeless and those with substance use disorders. A major theme of his research includes examining the efficacy, effectiveness, and implementation of evidence-based identification, assessment, and treatments for patients with addiction. His methodological skills include health services, clinical trial, large database, and implementation science research. He has received efforts on over 100 federal peer reviewed grants from the NIH, VA, AHRQ, PCORI, and SAMHSA. He has authored over 310 peer reviewed articles (15.3% first authored, 27.2% senior authored, 40.8% authored with mentee) in high impact journals (e.g., JAMA, BMJ, Lancet; H-index=56) and presented/published hundreds of scholarly works. As evidence of how his research has impacted clinical care and my profession, he was awarded one of VA HSR&D’s highest honors by receipt of the 2021 VA Health Services Research and Development (HSR&D) “Health System Impact Award” and received the 2022 David C. Lewis, MD Service to Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) Award.

He has mentored undergraduate, graduate, MD, and PhD trainees, VA and K- Career Development Awardees, and junior through tenured faculty. In addition, his post-doctoral mentees have received research Career Development Awards and have obtained large research awards. He is a primary or secondary mentor on over a dozen current or prior VA, NIH K-, or institutional K-awards. He has been honored locally and nationally for his mentorship abilities: named as an inaugural VA Health Services Research and Development National Mentor Network (MNet) mentor, received the “Allen Humphrey Excellence in Medical Student Research Mentoring Award” from the University of Pittsburgh School of Medicine, and was the recipient of the 2013 W. Anderson Spickard, Jr. Excellence in Mentorship Award from Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA). His time allocation (for a 60-hour work week between the University and the VA is 80% research/mentoring, 10% clinical/education, 10% administration).

Board Certification and Academic Information

Academic Departments Internal Medicine -Professor
Psychiatry -Adjunct Professor
Academic Divisions Adult Psychiatry
Epidemiology
Board Certification
American Board of Addiction Medicine
American Board of Internal Medicine
American Board of Preventive Medicine (Addiction Medicine)

Education history

Undergraduate Biological Sciences - Northwestern University B.A.
Professional Medical Medicine - University of Pittsburgh School of Medicine M.D.
Internship/Residency Internal Medicine - University of Pittsburgh Medical Center Intern/Resident
Graduate Training Multidisciplinary - University of Pittsburgh Graduate School of Public Health M.P.H.
Fellowship General Internal Medicine - VA Pittsburgh Healthcare System/University of Pittsburgh Fellow

Selected Publications

Journal Article

  1. Conigliaro J, Madenwald T, Bryant K, Braithwaite S, Gordon A, Fultz SL, Maisto S, Samet J, Kraemer K, Cook R, Day N, Roach D, Richey S, Justice A (2004). The Veterans Aging Cohort Study: observational studies of alcohol use, abuse, and outcomes among human immunodeficiency virus-infected veterans. Alcohol Clin Exp Res, 28(2), 313-21.
  2. Braithwaite RS, McGinnis KA, Conigliaro J, Maisto SA, Crystal S, Day N, Cook RL, Gordon A, Bridges MW, Seiler JF, Justice AC (2005). A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res, 29(7), 1190-7.
  3. Broyles LM, Rosenberger E, Hanusa BH, Kraemer KL, Gordon AJ (2012). Hospitalized patients' acceptability of nurse-delivered screening, brief intervention, and referral to treatment. Alcohol Clin Exp Res, 36(4), 725-31.
  4. Caniglia EC, Stevens ER, Khan M, Young KE, Ban K, Marshall BDL, Chichetto NE, Gaither JR, Crystal S, Edelman EJ, Fiellin DA, Gordon AJ, Bryant KJ, Tate J, Justice AC, Braithwaite RS (2020). Does Reducing Drinking in Patients with Unhealthy Alcohol Use Improve Pain Interference, Use of Other Substances, and Psychiatric Symptoms? Alcohol Clin Exp Res, 44(11), 2257-2265.
  5. Gordon AJ, Macpherson DS (2003). Guideline chaos: conflicting recommendations for preoperative cardiac assessment. Am J Cardiol, 91(11), 1299-303.
  6. Oliva EM, Trafton JA, Harris AH, Gordon AJ (2013). Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse, 39(2), 103-7.
  7. Andraka-Christou B, Bouskill K, Haffajee RL, Randall-Kosich O, Golan M, Totaram R, Gordon AJ, Stein BD (2021). Common themes in early state policy responses to substance use disorder treatment during COVID-19.(Epub ahead of print) Am J Drug Alcohol Abuse, 1-11.
  8. Codell N, Kelley AT, Jones AL, Dungan MT, Valentino N, Holtey AI, Knight TJ, Butz A, Gallop C, Erickson S, Patton J, Hyte-Richins LJ, Rollins BZ, Gordon AJ (2021). Aims, development, and early results of an interdisciplinary primary care initiative to address patient vulnerabilities. Am J Drug Alcohol Abuse, 47(2), 160-169.
  9. Gordon AJ, Montlack ML, Freyder P, Johnson D, Bui T, Williams J (2007). The Allegheny initiative for mental health integration for the homeless: integrating heterogeneous health services for homeless persons. Am J Public Health, 97(3), 401-5.
  10. Kertesz SG, Holt CL, Steward JL, Jones RN, Roth DL, Stringfellow E, Gordon AJ, Kim TW, Austin EL, Henry SR, Kay Johnson N, Shanette Granstaff U, O'Connell JJ, Golden JF, Young AS, Davis LL, Pollio DE (2013). Comparing homeless persons' care experiences in tailored versus nontailored primary care programs. Am J Public Health, 103 Suppl 2, S331-9.
  11. Blosnich JR, Gordon AJ, Bossarte RM (2014). Suicidal ideation and mental distress among adults with military service history: results from 5 U.S. states, 2010. Am J Public Health, 104 Suppl 4, S595-602.
  12. Blosnich JR, Marsiglio MC, Gao S, Gordon AJ, Shipherd JC, Kauth M, Brown GR, Fine MJ (2016). Mental Health of Transgender Veterans in US States With and Without Discrimination and Hate Crime Legal Protection. Am J Public Health, 106(3), 534-40.
  13. Gellad WF, Thorpe JM, Zhao X, Thorpe CT, Sileanu FE, Cashy JP, Hale JA, Mor MK, Radomski TR, Hausmann LRM, Donohue JM, Gordon AJ, Suda KJ, Stroupe KT, Hanlon JT, Cunningham FE, Good CB, Fine MJ (2018). Impact of Dual Use of Department of Veterans Affairs and Medicare Part D Drug Benefits on Potentially Unsafe Opioid Use. Am J Public Health, 108(2), 248-255.
  14. Carter SP, Montgomery AE, Henderson ER, Ketterer B, Dichter M, Gordon AJ, Shipherd JC, Kauth MR, Blosnich JR (2019). Housing Instability Characteristics Among Transgender Veterans Cared for in the Veterans Health Administration, 2013-2016. Am J Public Health, 109(10), 1413-1418.
  15. Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA (2011). When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med, 154(8), 509-15.
  16. Gordon AJ, Wentz CM, Gibbon JL, Mason AD, Freyder PJ, O'Toole TP (2001). Relationships between patient characteristics and unsuccessful substance abuse detoxification. J Addict Dis, 20(2), 41-53.
  17. Stein BD, Mendelsohn J, Gordon AJ, Dick AW, Burns RM, Sorbero M, Shih RA, Liccardo Pacula R (2017). Opioid analgesic and benzodiazepine prescribing among Medicaid-enrollees with opioid use disorders: The influence of provider communities. J Addict Dis, 36(1), 14-22.
  18. Goldstein G, Luther JF, Jacoby AM, Haas GL, Gordon AJ (2008). A Taxonomy of medical comorbidity for veterans who are homeless. J Health Care Poor Underserved, 19(3), 991-1005.
  19. del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Perez-Hoyos S, Jarrin I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miro JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernan MA (2012). Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis, 54(9), 1364-72.
  20. Armah KA, McGinnis K, Baker J, Gibert C, Butt AA, Bryant KJ, Goetz M, Tracy R, Oursler KK, Rimland D, Crothers K, Rodriguez-Barradas M, Crystal S, Gordon A, Kraemer K, Brown S, Gerschenson M, Leaf DA, Deeks SG, Rinaldo C, Kuller LH, Justice A, Freiberg M (2012). HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis, 55(1), 126-36.
  21. Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Lo Re V 3rd (2014). Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis, 58(10), 1449-58.
  22. Korthuis PT, McGinnis KA, Kraemer KL, Gordon AJ, Skanderson M, Justice AC, Crystal S, Goetz MB, Gibert CL, Rimland D, Fiellin LE, Gaither JR, Wang K, Asch SM, McInnes DK, Ohl ME, Bryant K, Tate JP, Duggal M, Fiellin DA (2016). Quality of HIV Care and Mortality Rates in HIV-Infected Patients. Clin Infect Dis, 62(2), 233-239.
  23. Strobel B, McManus L, Leong S, Blow F, Slaymaker V, Berrettini W, Gordon AJ, O'Brien C, Oslin D (2013). A cross-sectional study of attitudes about the use of genetic testing for clinical care among patients with an alcohol use disorder. Alcohol Alcohol, 48(6), 700-3.
  24. Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Perez-Hoyos S, Garcia de Olalla P, Hernan MA (2010). The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS, 24(1), 123-37.
  25. Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernan MA (2012). The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS, 26(13), 1691-705.
  26. Depp TB, McGinnis KA, Kraemer K, Akgun KM, Edelman EJ, Fiellin DA, Butt AA, Crystal S, Gordon AJ, Freiberg M, Gibert CL, Rimland D, Bryant KJ, Crothers K (2016). Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients. AIDS, 30(3), 455-63.
  27. Blosnich JR, Marsiglio MC, Dichter ME, Gao S, Gordon AJ, Shipherd JC, Kauth MR, Brown GR, Fine MJ (2017). Impact of Social Determinants of Health on Medical Conditions Among Transgender Veterans. Am J Prev Med, 52(4), 491-498.
  28. Moyo P, Gellad WF, Sabik LM, Cochran GT, Cole ES, Gordon AJ, Kelley DK, Donohue JM (2019). Opioid Prescribing Safety Measures in Medicaid Enrollees With and Without Cancer. Am J Prev Med, 57(4), 540-544.
  29. Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, Kelley D, Donohue JM (2016). Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction, 111(5), 892-902.
  30. Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerdá M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BD (2016). Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study. Addiction, 111(11), 2021-2031.
  31. Kertesz SG, Gordon AJ (2019). A crisis of opioids and the limits of prescription control: United States. Addiction, 114(1), 169-180.
  32. Lin LA, Bohnert ASB, Blow FC, Gordon AJ, Ignacio RV, Kim HM, Ilgen MA (2021). Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction, 116(1), 96-104.
  33. Oliva EM, Bowe T, Manhapra A, Kertesz S, Hah JM, Henderson P, Robinson A, Paik M, Sandbrink F, Gordon AJ, Trafton JA (2020). Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ, 368, m283.
  34. Varley AL, Montgomery AE, Steward J, Stringfellow E, Austin EL, Gordon AJ, Pollio D, deRussy A, Hoge A, Gelberg L, Riggs K, Kim TW, Rubens SL, Kertesz SG (2020). Exploring Quality of Primary Care for Patients Who Experience Homelessness and the Clinicians Who Serve Them: What Are Their Aspirations? Qual Health Res, 30(6), 865-879.
  35. Kertesz SG, Manhapra A, Gordon A (2020). Nonconsensual Dose Reduction Mandates are Not Justified Clinically or Ethically: An Analysis. The Journal of law, medicine & ethics, 48(2), 259-267.
  36. Blosnich JR, Gordon AJ, Fine M (2015). Associations of sexual and gender minority status with health indicators, health risk factors, and social stressors in a national sample of young adults with military experience. Annals of epidemiology, 25(9), 661-7.
  37. Smid MC, Metz TD, Gordon A (2019). Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. Clinical obstetrics and gynecology, 62(1), 168-184.
  38. Long JA, Wang A, Medvedeva EL, Eisen SV, Gordon AJ, Kreyenbuhl J, Marcus S (2014). Glucose control and medication adherence among veterans with diabetes and serious mental illness: does collocation of primary care and mental health care matter?. Diabetes care, 37(8), 2261-7.
  39. Gordon AJ, Trafton JA, Saxon AJ, Gifford AL, Goodman F, Calabrese VS, McNicholas L, Liberto (2007). Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. Drug and alcohol dependence, 90(2-3), 292-6.
  40. Green TC, Kershaw T, Lin H, Heimer R, Goulet JL, Kraemer KL, Gordon AJ, Maisto SA, Day NL, Bryant K, Fiellin DA, Justice A (2010). Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug and alcohol dependence, 110(3), 208-20.
  41. Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer (2012). The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug and alcohol dependence, 123(1-3), 72-8.
  42. Oliva EM, Harris AH, Trafton JA, Gordon A (2012). Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Drug and alcohol dependence, 122(3), 241-6.
  43. Ghose T, Fiellin DA, Gordon AJ, Metraux S, Goetz MB, Blackstock O, McInnes K, Rodriguez-Barradas MC, Justice A (2013). Hazardous drinking and its association with homelessness among veterans in care. Drug and alcohol dependence, 132(1-2), 202-6.
  44. Marshall BD, Operario D, Bryant KJ, Cook RL, Edelman EJ, Gaither JR, Gordon AJ, Kahler CW, Maisto SA, McGinnis KA, van den Berg JJ, Zaller ND, Justice AC, Fiellin D (2015). Drinking trajectories among HIV-infected men who have sex with men: a cohort study of United States veterans. Drug and alcohol dependence, 148, 69-76.
  45. Justice AC, McGinnis KA, Tate JP, Braithwaite RS, Bryant KJ, Cook RL, Edelman EJ, Fiellin LE, Freiberg MS, Gordon AJ, Kraemer KL, Marshall BD, Williams EC, Fiellin D (2016). Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug and alcohol dependence, 161, 95-103.
  46. McGinnis KA, Tate JP, Williams EC, Skanderson M, Bryant KJ, Gordon AJ, Kraemer KL, Maisto SA, Crystal S, Fiellin DA, Justice A (2016). Comparison of AUDIT-C collected via electronic medical record and self-administered research survey in HIV infected and uninfected patients. Drug and alcohol dependence, 168, 196-202.
  47. Cochran G, McCarthy R, Gordon AJ, Tarter R (2017). Opioid medication misuse among unhealthy drinkers. Drug and alcohol dependence, 179, 13-17.
  48. Lin LA, Lofwall MR, Walsh SL, Gordon AJ, Knudsen H (2018). Perceptions and practices addressing diversion among US buprenorphine prescribers. Drug and alcohol dependence, 186, 147-153.
  49. Williams EC, McGinnis KA, Bobb JF, Rubinsky AD, Lapham GT, Skanderson M, Catz SL, Bensley KM, Richards JE, Bryant KJ, Edelman EJ, Satre DD, Marshall BDL, Kraemer KL, Blosnich JR, Crystal S, Gordon AJ, Fiellin DA, Justice AC, Bradley K (2018). Changes in alcohol use associated with changes in HIV disease severity over time: A national longitudinal study in the Veterans Aging Cohort. Drug and alcohol dependence, 189, 21-29.
  50. Barry DT, Marshall BDL, Becker WC, Gordon AJ, Crystal S, Kerns RD, Gaither JR, Gordon KS, Justice AC, Fiellin DA, Edelman E (2018). Duration of opioid prescriptions predicts incident nonmedical use of prescription opioids among U.S. veterans receiving medical care. Drug and alcohol dependence, 191, 348-354.
  51. Wyse JJ, Robbins JL, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Gaither JR, Gordon K, Skanderson M, Barry DT, Crystal S, Justice A, Kraemer K (2019). Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug and alcohol dependence, 198, 70-75.
  52. Cochran G, Chen Q, Field C, Seybert AL, Hruschak V, Jaber A, Gordon AJ, Tarter (2019). A community pharmacy-led intervention for opioid medication misuse: A small-scale randomized clinical trial. Drug and alcohol dependence, 205, 107570.
  53. Cole ES, Drake C, DiDomenico E, Sharbaugh M, Kim JY, Nagy D, Cochran G, Gordon AJ, Gellad WF, Pringle J, Warwick J, Chang CH, Kmiec J, Kelley D, Donohue J (2021). Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population. Drug and alcohol dependence, 221, 108633.
  54. McGinnis KA, Skanderson M, Edelman EJ, Gordon AJ, Korthuis PT, Oldfield B, Williams EC, Wyse J, Bryant K, Fiellin DA, Justice AC, Kraemer K (2020). Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. Drug and alcohol dependence, 217, 108272.
  55. Dick AW, Pacula RL, Gordon AJ, Sorbero M, Burns RM, Leslie D, Stein B (2015). Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11. Health affairs (Project Hope), 34(6), 1028-34.
  56. Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, Robins JM, Abgrall S, Shepherd BE, Deeks SG, John Gill M, Touloumi G, Vourli G, Dabis F, Vandenhende MA, Reiss P, van Sighem A, Samji H, Hogg RS, Rybniker J, Sabin CA, Jose S, Del Amo J, Moreno S, Rodriguez B, Cozzi-Lepri A, Boswell SL, Stephan C, Perez-Hoyos S, Jarrin I, Guest JL, D'Arminio Monforte A, Antinori A, Moore R, Campbell CN, Casabona J, Meyer L, Seng R, Phillips AN, Bucher HC, Egger M, Mugavero MJ, Haubrich R, Geng EH, Olson A, Eron JJ, Napravnik S, Kitahata MM, Van Rompaey SE, Teira R, Justice AC, Tate JP, Costagliola D, Sterne JA, Hernan M (2016). Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International journal of epidemiology, 45(6), 2038-2049.
  57. Gordon AJ, Maisto SA, McNeil M, Kraemer KL, Conigliaro RL, Kelley ME, Conigliaro (2001). Three questions can detect hazardous drinkers. The Journal of family practice, 50(4), 313-20.
  58. Kraemer KL, Maisto SA, Conigliaro J, McNeil M, Gordon AJ, Kelley M (2002). Decreased alcohol consumption in outpatient drinkers is associated with improved quality of life and fewer alcohol-related consequences. Journal of general internal medicine, 17(5), 382-6.
  59. Cook RL, McGinnis KA, Samet JH, Fiellin DA, Rodriguez-Barradas MC, Kraemer KL, Gibert CL, Braithwaite RS, Goulet JL, Mattocks K, Crystal S, Gordon AJ, Oursler KK, Justice A (2010). Erectile dysfunction drug receipt, risky sexual behavior and sexually transmitted diseases in HIV-infected and HIV-uninfected men. Journal of general internal medicine, 25(2), 115-21.
  60. Edelman EJ, Gordon K, Becker WC, Goulet JL, Skanderson M, Gaither JR, Brennan Braden J, Gordon AJ, Kerns RD, Justice AC, Fiellin D (2013). Receipt of opioid analgesics by HIV-infected and uninfected patients. Journal of general internal medicine, 28(1), 82-90.
  61. Jones AL, Mor MK, Cashy JP, Gordon AJ, Haas GL, Schaefer JH Jr, Hausmann L (2016). Racial/Ethnic Differences in Primary Care Experiences in Patient-Centered Medical Homes among Veterans with Mental Health and Substance Use Disorders. Journal of general internal medicine, 31(12), 1435-1443.
  62. Radomski TR, Bixler FR, Zickmund SL, Roman KM, Thorpe CT, Hale JA, Sileanu FE, Hausmann LRM, Thorpe JM, Suda KJ, Stroupe KT, Gordon AJ, Good CB, Fine MJ, Gellad W (2018). Physicians' Perspectives Regarding Prescription Drug Monitoring Program Use Within the Department of Veterans Affairs: a Multi-State Qualitative Study. Journal of general internal medicine, 33(8), 1253-1259.
  63. Cole ES, DiDomenico E, Cochran G, Gordon AJ, Gellad WF, Pringle J, Warwick J, Chang CH, Kim JY, Kmiec J, Kelley D, Donohue J (2019). The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder. Journal of general internal medicine, 34(6), 936-943.
  64. Jones AL, Mor MK, Haas GL, Gordon AJ, Cashy JP, Schaefer JH Jr, Hausmann LR (2018). The Role of Primary Care Experiences in Obtaining Treatment for Depression. Journal of general internal medicine, 33(8), 1366-1373.
  65. Blosnich JR, Montgomery AE, Dichter ME, Gordon AJ, Kavalieratos D, Taylor L, Ketterer B, Bossarte R (2020). Social Determinants and Military Veterans' Suicide Ideation and Attempt: a Cross-sectional Analysis of Electronic Health Record Data. Journal of general internal medicine, 35(6), 1759-1767.
  66. Guo J, Lo-Ciganic WH, Yang Q, Huang JL, Weiss JC, Cochran G, Malone DC, Kuza CC, Gordon AJ, Donohue JM, Gellad W (2021). Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose. Journal of general internal medicine, 36(4), 908-915.
  67. Clark DB, Martin CS, Chung T, Gordon AJ, Fiorentino L, Tootell M, Rubio D (2016). Screening for Underage Drinking and Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Alcohol Use Disorder in Rural Primary Care Practice. The Journal of pediatrics, 173, 214-20.
  68. Nevid JS, Gordon AJ, Haggerty (2020). Clinical Utility of the Personality Assessment Inventory in Predicting Symptom Change and Clinical Outcome in an Inpatient Chemical Dependency Rehabilitation Unit. Journal of personality assessment, 102(5), 587-593.
  69. Gordon AJ, Ettaro L, Rodriguez KL, Mocik J, Clark D (2011). Provider, patient, and family perspectives of adolescent alcohol use and treatment in rural settings. The Journal of rural health, 27(1), 81-90.
  70. Gordon AJ, Choi JH, Ginsburg H, Kuenzler K, Fisher J, Tomita (2020). Oral Antibiotics and Abscess Formation After Appendectomy for Perforated Appendicitis in Children. The Journal of surgical research, 256, 56-60.
  71. Stein BD, Gordon AJ, Dick AW, Burns RM, Pacula RL, Farmer CM, Leslie DL, Sorbero (2015). Supply of buprenorphine waivered physicians: the influence of state policies. Journal of substance abuse treatment, 48(1), 104-11.
  72. Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Lo Re V 3rd, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin D (2016). Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal of substance abuse treatment, 68, 62-7.
  73. Nevid JS, Gordon AJ, Barris A, Sperber JE, Haggerty (2019). Personality profiles of patients with alcohol use disorder and opioid use disorder in an inpatient treatment setting. Journal of substance abuse treatment, 97, 91-96.
  74. Kraemer KL, McGinnis KA, Fiellin DA, Skanderson M, Gordon AJ, Robbins J, Zickmund S, Bryant K, Korthuis P (2019). Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans. Journal of substance abuse treatment, 103, 23-32.
  75. Oldfield BJ, McGinnis KA, Edelman EJ, Williams EC, Gordon AJ, Akgün K, Crystal S, Fiellin LE, Gaither JR, Goulet JL, Korthuis PT, Marshall BDL, Justice AC, Bryant K, Fiellin DA, Kraemer K (2020). Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. Journal of substance abuse treatment, 109, 14-22.
  76. Jones AL, Kertesz SG, Hausmann LRM, Mor MK, Suo Y, Pettey WBP, Schaefer JH Jr, Gundlapalli AV, Gordon A (2020). Primary care experiences of veterans with opioid use disorder in the Veterans Health Administration. Journal of substance abuse treatment, 113, 107996.
  77. Kennedy AJ, McGinnis KA, Merlin JS, Edelman EJ, Gordon AJ, Korthuis PT, Skanderson M, Williams EC, Wyse J, Oldfield B, Bryant K, Justice A, Fiellin DA, Kraemer K (2021). Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. Journal of substance abuse treatment, 132, 108509.
  78. Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon A (2016). Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment. JAMA, 316(11), 1211-1212.
  79. Frazier W, Cochran G, Lo-Ciganic WH, Gellad WF, Gordon AJ, Chang CH, Donohue J (2017). Medication-Assisted Treatment and Opioid Use Before and After Overdose in Pennsylvania Medicaid. JAMA, 318(8), 750-752.
  80. Stein BD, Saloner B, Schuler MS, Gurvey J, Sorbero M, Gordon A (2021). Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US. JAMA, 325(21), 2206-2208.
  81. Clark DB, Gordon AJ, Ettaro LR, Owens JM, Moss H (2010). Screening and brief intervention for underage drinkers. Mayo Clinic proceedings, 85(4), 380-91.
  82. Conigliaro J, Justice AC, Gordon AJ, Bryant K, VACS Alcohol and Behavior Change Research Group (2006). Role of alcohol in determining human immunodeficiency virus (HIV)-relevant outcomes: A conceptual model to guide the implementation of evidence-based interventions into practice. Medical care, 44(8 Suppl 2), S1-6.
  83. Cook RL, McGinnis KA, Kraemer KL, Gordon AJ, Conigliaro J, Maisto SA, Samet JH, Crystal S, Rimland D, Bryant KJ, Braithwaite RS, Justice A (2006). Intoxication before intercourse and risky sexual behavior in male veterans with and without human immunodeficiency virus infection. Medical care, 44(8 Suppl 2), S31-6.
  84. Gordon AJ, McGinnis KA, Conigliaro J, Rodriguez-Barradas MC, Rabeneck L, Justice A (2006). Associations between alcohol use and homelessness with healthcare utilization among human immunodeficiency virus-infected veterans. Medical care, 44(8 Suppl 2), S37-43.
  85. Kraemer KL, McGinnis KA, Skanderson M, Cook R, Gordon A, Conigliaro J, Shen Y, Fiellin DA, Justice A (2006). Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans. Medical care, 44(8 Suppl 2), S44-51.
  86. Goulet JL, Brandt C, Crystal S, Fiellin DA, Gibert C, Gordon AJ, Kerns RD, Maisto S, Justice A (2013). Agreement between electronic medical record-based and self-administered pain numeric rating scale: clinical and research implications. Medical care, 51(3), 245-50.
  87. Kertesz SG, Pollio DE, Jones RN, Steward J, Stringfellow EJ, Gordon AJ, Johnson NK, Kim TA, Daigle SG, Austin EL, Young AS, Chrystal JG, Davis LL, Roth DL, Holt C (2014). Development of the Primary Care Quality-Homeless (PCQ-H) instrument: a practical survey of homeless patients' experiences in primary care. Medical care, 52(8), 734-42.
  88. Cochran G, Gordon AJ, Lo-Ciganic WH, Gellad WF, Frazier W, Lobo C, Chang CH, Zheng P, Donohue J (2017). An Examination of Claims-based Predictors of Overdose from a Large Medicaid Program. Medical care, 55(3), 291-298.
  89. Bukowski LA, Blosnich J, Shipherd JC, Kauth MR, Brown GR, Gordon A (2017). Exploring Rural Disparities in Medical Diagnoses Among Veterans With Transgender-related Diagnoses Utilizing Veterans Health Administration Care. Medical care, 55 Suppl 9 Suppl 2, S97-S103.
  90. Jones AL, Hausmann LRM, Kertesz S, Suo Y, Cashy JP, Mor MK, Schaefer JH Jr, Gundlapalli AV, Gordon A (2018). Differences in Experiences With Care Between Homeless and Nonhomeless Patients in Veterans Affairs Facilities With Tailored and Nontailored Primary Care Teams. Medical care, 56(7), 610-618.
  91. Jones AL, Hausmann LRM, Kertesz SG, Suo Y, Cashy JP, Mor MK, Pettey WBP, Schaefer JH Jr, Gordon AJ, Gundlapalli A (2019). Providing Positive Primary Care Experiences for Homeless Veterans Through Tailored Medical Homes: The Veterans Health Administration's Homeless Patient Aligned Care Teams. Medical care, 57(4), 270-278.
  92. Jones AL, Gordon AJ, Gabrielian SE, Montgomery AE, Blosnich JR, Varley AL, deRussy AJ, Austin EL, Hoge AE, Kim YI, Gelberg L, Kertesz S (2021). Perceptions of Care Coordination Among Homeless Veterans Receiving Medical Care in the Veterans Health Administration and Community Care Settings: Results From a National Survey. Medical care, 59(6), 504-512.
  93. Kertesz SG, deRussy AJ, Kim YI, Hoge AE, Austin EL, Gordon AJ, Gelberg L, Gabrielian SE, Riggs KR, Blosnich JR, Montgomery AE, Holmes SK, Varley AL, Pollio DE, Gundlapalli AV, Jones A (2021). Comparison of Patient Experience Between Primary Care Settings Tailored for Homeless Clientele and Mainstream Care Settings. Medical care, 59(6), 495-503.
  94. Stein BD, Pacula RL, Gordon AJ, Burns RM, Leslie DL, Sorbero MJ, Bauhoff S, Mandell TW, Dick A (2015). Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties. The Milbank quarterly, 93(3), 561-83.
  95. Smid M, Gordon AJ, Plumb S, Plumb (2018). Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstetrics and gynecology, 131(1), 163-164.
  96. Smid MC, Charles JE, Gordon AJ, Wright T (2018). Use of Kratom, an Opioid-like Traditional Herb, in Pregnancy. Obstetrics and gynecology, 132(4), 926-928.
  97. Smid MC, Stone NM, Baksh L, Debbink MP, Einerson BD, Varner MW, Gordon AJ, Clark EA (2019). Pregnancy-Associated Death in Utah: Contribution of Drug-Induced Deaths. Obstetrics and gynecology, 133(6), 1131-1140.
  98. Gordon A (1999). Residency and volunteerism: not mutually exclusive. Pennsylvania medicine, 102(6), 13.
  99. Gordon A (1999). Clinical evidence: marijuana a useful medicine. Pennsylvania medicine, 102(1), 3.
  100. Barry DT, Goulet JL, Kerns RK, Becker WC, Gordon AJ, Justice AC, Fiellin D (2011). Nonmedical use of prescription opioids and pain in veterans with and without HIV. Pain, 152(5), 1133-1138.
  101. Banerjee G, Edelman EJ, Barry DT, Crystal S, Gordon KS, Gordon AJ, Gaither JR, Green TC, Kerns RD, Manhapra A, Moore BA, Fiellin DA, Marshall BD (2019). High-dose prescribed opioids are associated with increased risk of heroin use among United States military veterans. Pain, 160(9), 2126-2135.
  102. Gordon AJ, Olstein J, Conigliaro (2006). Identification and treatment of alcohol use disorders in the perioperative period. Postgraduate medicine, 119(2), 46-55.
  103. Sevick MA, Napolitano MA, Papandonatos GD, Gordon AJ, Reiser LM, Marcus B (2007). Cost-effectiveness of alternative approaches for motivating activity in sedentary adults: results of Project STRIDE. Preventive medicine, 45(1), 54-61.
  104. McLellan AT, Starrels JL, Tai B, Gordon AJ, Brown R, Ghitza U, Gourevitch M, Stein J, Oros M, Horton T, Lindblad R, McNeely (2014). Can Substance Use Disorders be Managed Using the Chronic Care Model? Review and Recommendations from a NIDA Consensus Group. Public health reviews, 35(2),
  105. Goldstein G, Luther JF, Haas GL, Gordon AJ, Appelt (2009). Comorbidity between psychiatric and general medical disorders in homeless veterans. The Psychiatric quarterly, 80(4), 199-212.
  106. Goldstein G, Luther JF, Haas GL, Appelt CJ, Gordon A (2010). Factor structure and risk factors for the health status of homeless veterans. The Psychiatric quarterly, 81(4), 311-23.
  107. King JT Jr, Gordon AJ, Perkal MF, Crystal S, Rosenthal RA, Rodriguez-Barradas MC, Butt AA, Gibert CL, Rimland D, Simberkoff MS, Justice A (2012). Disparities in rates of spine surgery for degenerative spine disease between HIV-infected and uninfected veterans. Spine, 37(7), 612-22.
  108. Ghose T, Gordon AJ, Metraux S, Justice A (2011). Mental illness and homelessness among veterans. Psychiatric services (Washington, D.C.), 62(12), 1514-5.
  109. Blosnich JR, Cashy J, Gordon AJ, Shipherd JC, Kauth MR, Brown GR, Fine M (2018). Using clinician text notes in electronic medical record data to validate transgender-related diagnosis codes. Journal of the American Medical Informatics Association, 25(7), 905-908.
  110. Liu F, Pradhan R, Druhl E, Freund E, Liu W, Sauer BC, Cunningham F, Gordon AJ, Peters CB, Yu (2019). Learning to detect and understand drug discontinuation events from clinical narratives. Journal of the American Medical Informatics Association, 26(10), 943-951.
  111. Gordon AJ, Conigliaro J, Maisto SA, McNeil M, Kraemer KL, Kelley M (2003). Comparison of consumption effects of brief interventions for hazardous drinking elderly. Substance use & misuse, 38(8), 1017-35.
  112. Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andree T, McNicholas (2008). Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. The American journal on addictions, 17(6), 459-62.
  113. Lan CW, Fiellin DA, Barry DT, Bryant KJ, Gordon AJ, Edelman EJ, Gaither JR, Maisto SA, Marshall B (2016). The epidemiology of substance use disorders in US Veterans: A systematic review and analysis of assessment methods. The American journal on addictions, 25(1), 7-24.
  114. Becker WC, Gordon K, Edelman EJ, Kerns RD, Crystal S, Dziura JD, Fiellin LE, Gordon AJ, Goulet JL, Justice AC, Fiellin D (2016). Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV. AIDS and behavior, 20(3), 679-86.
  115. McGinnis KA, Fiellin DA, Tate JP, Cook RL, Braithwaite RS, Bryant KJ, Edelman EJ, Gordon AJ, Kraemer KL, Maisto SA, Justice A (2016). Number of Drinks to "Feel a Buzz" by HIV Status and Viral Load in Men. AIDS and behavior, 20(3), 504-11.
  116. Becker WC, Gordon K, Edelman EJ, Kerns RD, Crystal S, Dziura JD, Fiellin LE, Gordon AJ, Goulet JL, Justice AC, Fiellin D (2017). Erratum to: Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV. AIDS and behavior, 21(4), 1228.
  117. Adams JW, Bryant KJ, Edelman EJ, Fiellin DA, Gaither JR, Gordon AJ, Gordon KS, Kraemer KL, Mimiaga MJ, Operario D, Tate JP, van den Berg JJ, Justice AC, Marshall BD (2018). Association of Cannabis, Stimulant, and Alcohol use with Mortality Prognosis Among HIV-Infected Men. AIDS and behavior, 22(4), 1341-1351.
  118. Williams EC, McGinnis KA, Edelman EJ, Matson TE, Gordon AJ, Marshall BDL, Bryant KJ, Rubinsky AD, Lapham GT, Satre DD, Richards JE, Catz SL, Fiellin DA, Justice AC, Bradley K (2019). Level of Alcohol Use Associated with HIV Care Continuum Targets in a National U.S. Sample of Persons Living with HIV Receiving Healthcare. AIDS and behavior, 23(1), 140-151.
  119. Rentsch CT, Edelman EJ, Justice AC, Marshall BDL, Xu K, Smith AH, Crystal S, Gaither JR, Gordon AJ, Smith RV, Kember RL, Polimanti R, Gelernter J, Fiellin DA, Tate JP, Kranzler HR, Becker WC, VACS Project Team (2019). Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study. AIDS and behavior, 23(12), 3340-3349.
  120. Williams EC, McGinnis KA, Rubinsky AD, Matson TE, Bobb JF, Lapham GT, Edelman EJ, Satre DD, Catz SL, Richards JE, Bryant KJ, Marshall BDL, Kraemer KL, Crystal S, Gordon AJ, Skanderson M, Fiellin DA, Justice AC, Bradley K (2021). Alcohol Use and Antiretroviral Adherence Among Patients Living with HIV: Is Change in Alcohol Use Associated with Change in Adherence?. AIDS and behavior, 25(1), 203-214.
  121. Cochran G, Gordon AJ, Gellad WF, Chang CH, Lo-Ciganic WH, Lobo C, Cole E, Frazier W, Zheng P, Kelley D, Donohue J (2017). Medicaid prior authorization and opioid medication abuse and overdose. The American journal of managed care, 23(5), e164-e171.
  122. Gordon AJ, Kavanagh G, Krumm M, Ramgopal R, Paidisetty S, Aghevli M, Goodman F, Trafton J, Liberto (2011). Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychology of addictive behaviors, 25(2), 215-24.
  123. Conigliaro J, Gordon AJ, McGinnis KA, Rabeneck L, Justice AC, Veterans Aging Cohort 3-Site Study (2003). How harmful is hazardous alcohol use and abuse in HIV infection: do health care providers know who is at risk?. Journal of acquired immune deficiency syndromes (1999), 33(4), 521-5.
  124. Korthuis PT, Fiellin DA, McGinnis KA, Skanderson M, Justice AC, Gordon AJ, Doebler DA, Asch SM, Fiellin LE, Bryant K, Gibert CL, Crystal S, Goetz MB, Rimland D, Rodriguez-Barradas MC, Kraemer K (2012). Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. Journal of acquired immune deficiency syndromes (1999), 61(2), 171-8.
  125. Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, Gaither J, Gordon AJ, Goulet J, Kerns RD, Moore BA, Tate J, Justice AC, Fiellin D (2015). Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. Journal of acquired immune deficiency syndromes (1999), 69(2), 223-33.
  126. Eyawo O, McGinnis KA, Justice AC, Fiellin DA, Hahn JA, Williams EC, Gordon AJ, Marshall BDL, Kraemer KL, Crystal S, Gaither JR, Edelman EJ, Bryant KJ, Tate JP, VACS Project team (2018). Alcohol and Mortality: Combining Self-Reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected. Journal of acquired immune deficiency syndromes (1999), 77(2), 135-143.
  127. Oliva EM, Maisel NC, Gordon AJ, Harris A (2011). Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Current psychiatry reports, 13(5), 374-81.
  128. Gordon AJ, Conley JW, Gordon J (2013). Medical consequences of marijuana use: a review of current literature. Current psychiatry reports, 15(12), 419.
  129. McCall JD, Rodriguez KL, Barnisin-Lange D, Gordon A (2019). A Qualitative Examination of the Experiences of Veterans Treatment Court Graduates in Allegheny County, Pennsylvania. International journal of offender therapy and comparative criminology, 63(3), 339-356.
  130. Edelman EJ, Gordon KS, Tate JP, Becker WC, Bryant K, Crothers K, Gaither JR, Gibert CL, Gordon AJ, Marshall B, Rodriguez-Barradas MC, Samet JH, Skanderson M, Justice AC, Fiellin D (2016). The impact of prescribed opioids on CD4 cell count recovery among HIV-infected patients newly initiating antiretroviral therapy. HIV medicine, 17(10), 728-739.
  131. Mays DM, Gordon AJ, Kelly ME, Forman S (2005). Violent criminal behavior and perspectives on treatment of criminality in opiate treatment. Substance abuse, 26(2), 33-42.
  132. Mays KL, Clark DL, Gordon A (2008). Treating addiction with tunes: a systematic review of music therapy for the treatment of patients with addictions. Substance abuse, 29(4), 51-9.
  133. Walley AY, Phillips KA, Gordon A (2008). The patients in recovery (PIR) perspective: teaching physicians about methamphetamine. Substance abuse, 29(4), 61-4.
  134. Broyles LM, Gordon AJ, Sereika SM, Ryan CM, Erlen J (2011). Do words matter? Incongruent responses to inconsistently worded AUDIT-C alcohol screening instruments. Substance abuse, 32(4), 202-9.
  135. Broyles LM, Gordon AJ, Sereika SM, Ryan CM, Erlen J (2011). Predictive Utility of Brief Alcohol Use Disorders Identification Test (AUDIT) for human immunodeficiency virus antiretroviral medication nonadherence. Substance abuse, 32(4), 252-61.
  136. Childers JW, Broyles LM, Hanusa BH, Kraemer KL, Conigliaro J, Spagnoletti C, McNeil M, Gordon A (2012). Teaching the teachers: faculty preparedness and evaluation of a retreat in screening, brief intervention, and referral to treatment. Substance abuse, 33(3), 272-7.
  137. Pringle JL, Melczak M, Johnjulio W, Campopiano M, Gordon AJ, Costlow (2012). Pennsylvania SBIRT Medical and Residency Training: developing, implementing, and evaluating an evidenced-based program. Substance abuse, 33(3), 292-7.
  138. Gordon AJ, Galanter M, Khalsa J (2014). Addressing addiction across borders: an international perspective on policies, scholarship, and collaboration. Substance abuse, 35(3), 290-1.
  139. Cochran G, Woo B, Lo-Ciganic WH, Gordon AJ, Donohue JM, Gellad W (2015). Defining Nonmedical Use of Prescription Opioids Within Health Care Claims: A Systematic Review. Substance abuse, 36(2), 192-202.
  140. Farmer CM, Lindsay D, Williams J, Ayers A, Schuster J, Cilia A, Flaherty MT, Mandell T, Gordon AJ, Stein B (2015). Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process. Substance abuse, 36(2), 209-16.
  141. Burns RM, Pacula RL, Bauhoff S, Gordon AJ, Hendrikson H, Leslie DL, Stein B (2016). Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013. Substance abuse, 37(1), 63-9.
  142. Stringfellow EJ, Kim TW, Gordon AJ, Pollio DE, Grucza RA, Austin EL, Johnson NK, Kertesz S (2016). Substance use among persons with homeless experience in primary care. Substance abuse, 37(4), 534-541.
  143. Mitchell MA, Broyles LM, Pringle JL, Kraemer KL, Childers JW, Buranosky RA, Gordon A (2017). Education for the mind and the heart? Changing residents' attitudes about addressing unhealthy alcohol use. Substance abuse, 38(1), 40-42.
  144. Narayanan AK, Harding JD Jr, Saba SK, Conley J, Gordon AJ Md Mp (2016). Left, right, and meeting in the middle: Addressing addiction is something we can agree about. Substance abuse, 37(4), 495-497.
  145. Gordon A (2017). Abstracts of the 18th Annual Meeting of the International Society of Addiction Medicine (ISAM)-2016. Substance abuse, 38(1), 2.
  146. Gordon A (2017). The 40th annual meeting of AMERSA: Highlights, abstracts, and awards. Substance abuse, 38(1), 1.
  147. Gordon AJ, Harding JD J (2017). From education to practice: Addressing opioid misuse through health care provider training: A special issue of Substance Abuse journal. Substance abuse, 38(2), 119-121.
  148. Levy S, Seale JP, Osborne VA, Kraemer KL, Alford DP, Baxter J, Finnell DS, Kunins H, Walley AY, Lewis DC, MacLane-Baeder D, Gordon A (2017). The Surgeon General's Facing Addiction report: An historic document for health care. Substance abuse, 38(2), 122.
  149. Pringle JL, Kearney SM, Rickard-Aasen S, Campopiano MM, Gordon A (2017). A statewide screening, brief intervention, and referral to treatment (SBIRT) curriculum for medical residents: Differential implementation strategies in heterogeneous medical residency programs. Substance abuse, 38(2), 161-167.
  150. Mundkur ML, Gordon AJ, Kertesz S (2017). Will strict limits on opioid prescription duration prevent addiction? Advocating for evidence-based policymaking. Substance abuse, 38(3), 237-238.
  151. Sestito SF, Rodriguez KL, Saba SK, Conley JW, Mitchell MA, Gordon A (2017). Homeless veterans' experiences with substance use, recovery, and treatment through photo elicitation. Substance abuse, 38(4), 422-431.
  152. Jones AL, Thomas R, Hedayati DO, Saba SK, Conley J, Gordon A (2018). Patient predictors and utilization of health services within a medical home for homeless persons. Substance abuse, 39(3), 354-360.
  153. Gordon A (2018). Abstracts presented at the Association for Medical Education and Research in Substance Abuse (AMERSA) 41st Annual Conference, Washington, DC, USA, November 2017. Substance abuse, 39(1), 1.
  154. Gordon A (2018). Abstracts presented at the International Society of Addiction Medicine (ISAM) 19th Annual Meeting, Abu Dhabi, United Arab Emirates, October 2017. Substance abuse, 39(1), 2.
  155. Wyse JJ, Gordon AJ, Dobscha SK, Morasco BJ, Tiffany E, Drexler K, Sandbrink F, Lovejoy T (2018). Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Substance abuse, 39(2), 139-144.
  156. Stein BD, Dick AW, Sorbero M, Gordon AJ, Burns RM, Leslie DL, Pacula R (2018). A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Substance abuse, 39(4), 419-425.
  157. Valenstein-Mah H, Hagedorn H, Kay CL, Christopher ML, Gordon A (2018). Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration. Substance abuse, 39(3), 286-288.
  158. Saloner B, Andraka Christou B, Gordon AJ, Stein B (2021). It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver. Substance abuse, 42(2), 153-157.
  159. Hagle HN, Martin M, Winograd R, Merlin J, Finnell DS, Bratberg JP, Gordon AJ, Johnson C, Levy S, MacLane-Baeder D, Northup R, Weinstein Z, Lum P (2021). Dismantling racism against Black, Indigenous, and people of color across the substance use continuum: A position statement of the association for multidisciplinary education and research in substance use and addiction. Substance abuse, 42(1), 5-12.
  160. Gustavson AM, Gordon AJ, Kenny ME, McHenry H, Gronek J, Ackland PE, Hagedorn H (2020). Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder. Substance abuse, 41(4), 413-418.
  161. Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mhatre-Owens A, Dungan MT, Hagedorn (2020). Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Substance abuse, 41(3), 275-282.
  162. Darnall BD, Juurlink D, Kerns RD, Mackey S, Van Dorsten B, Humphreys K, Gonzalez-Sotomayor JA, Furlan A, Gordon AJ, Gordon DB, Hoffman DE, Katz J, Kertesz SG, Satel S, Lawhern RA, Nicholson KM, Polomano RC, Williamson OD, McAnally H, Kao MC, Schug S, Twillman R, Lewis TA, Stieg RL, Lorig K, Mallick-Searle T, West RW, Gray S, Ariens SR, Sharpe Potter J, Cowan P, Kollas CD, Laird D, Ingle B, Julian Grove J, Wilson M, Lockman K, Hodson F, Palackdharry CS, Fillingim RB, Fudin J, Barnhouse J, Manhapra A, Henson SR, Singer B, Ljosenvoor M, Griffith M, Doctor JN, Hardin K, London C, Mankowski J, Anderson A, Ellsworth L, Davis Budzinski L, Brandt B, Hartley G, Nickels Heck D, Zobrosky MJ, Cheek C, Wilson M, Laux CE, Datz G, Dunaway J, Schonfeld E, Cady M, LeDantec-Boswell T, Craigie M, Sturgeon J, Flood P, Giummarra M, Whelan J, Thorn BE, Martin RL, Schatman ME, Gregory MD, Kirz J, Robinson P, Marx JG, Stewart JR, Keck PS, Hadland SE, Murphy JL, Lumley MA, Brown KS, Leong MS, Fillman M, Broatch JW, Perez A, Watford K, Kruska K, Sophia You D, Ogbeide S, Kukucka A, Lawson S, Ray JB, Wade Martin T, Lakehomer JB, Burke A, Cohen RI, Grinspoon P, Rubenstein MS, Sutherland S, Walters K, Lovejoy (2019). International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on Forced Opioid Tapering. Pain medicine (Malden, Mass.), 20(3), 429-433.
  163. Lobo CP, Cochran G, Chang CH, Gellad WF, Gordon AJ, Jalal H, Lo-Ciganic WH, Karp JF, Kelley D, Donohue J (2020). Associations Between the Specialty of Opioid Prescribers and Opioid Addiction, Misuse, and Overdose Outcomes. Pain medicine (Malden, Mass.), 21(9), 1871-1890.
  164. Cochran G, Smid MC, Krans EE, Bryan MA, Gordon AJ, Lundahl B, Silipigni J, Haaland B, Tarter (2019). A pilot multisite study of patient navigation for pregnant women with opioid use disorder. Contemporary clinical trials, 87, 105888.
  165. Chinman M, Gellad WF, McCarthy S, Gordon AJ, Rogal S, Mor MK, Hausmann LR (2019). Protocol for evaluating the nationwide implementation of the VA Stratification Tool for Opioid Risk Management (STORM). Implementation science, 14(1), 5.
  166. Rogal SS, Chinman M, Gellad WF, Mor MK, Zhang H, McCarthy SA, Mauro GT, Hale JA, Lewis ET, Oliva EM, Trafton JA, Yakovchenko V, Gordon AJ, Hausmann LR (2020). Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative. Implementation science, 15(1), 48.
  167. Gordon AJ, Saitz (2004). Identification and treatment of alcohol use disorders in primary care. Journal of clinical outcomes management, 11(7), 444-60.
  168. Paidisetty S, Gordon A (2006). Pharmacologic management of alcohol use disorders in the primary care setting. Journal of clinical outcomes management, 13(11), 628-46.
  169. Gordon AJ, Haas GL, Luther JF, Hilton MT, Goldstein (2010). Personal, Medical, and Healthcare Utilization Among Homeless Veterans Served by Metropolitan and Nonmetropolitan Veteran Facilities. Psychological services, 7(2), 65-74.
  170. Harris AHS, Ellerbe L, Reeder RN, Bowe T, Gordon AJ, Hagedorn H, Oliva E, Lembke A, Kivlahan D, Trafton J (2013). Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychological services, 10(4), 410-419.
  171. Jones AL, Hausmann LRM, Haas GL, Mor MK, Cashy JP, Schaefer JH, Gordon A (2017). A national evaluation of homeless and nonhomeless veterans' experiences with primary care. Psychological services, 14(2), 174-183.
  172. Goldstein G, Luther JF, Jacoby AM, Haas GL, Gordon A (2008). A preliminary classification system for homeless Veterans with mental illness. Psychological services, 5, 36-48.
  173. Chrystal JG, Glover DL, Young AS, Whelan F, Austin EL, Johnson NK, Pollio DE, Holt CL, Stringfellow E, Gordon AJ, Kim TA, Daigle SG, Steward JL, Kertesz S (2015). Experience of primary care among homeless individuals with mental health conditions. PloS one, 10(2), e0117395.
  174. Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Kwoh CK, Donohue JM, Gordon AJ, Cochran G, Malone DC, Kuza CC, Gellad W (2020). Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: A prognostic study. PloS one, 15(7), e0235981.
  175. Cochran G, Gordon AJ, Field C, Bacci J, Dhital R, Ylioja T, Stitzer M, Kelly T, Tarter (2016). Developing a framework of care for opioid medication misuse in community pharmacy. Research in social & administrative pharmacy, 12(2), 293-301.
  176. Maisto SA, Conigliaro JC, Gordon AJ, McGinnis KA, Justice A (2008). An experimental study of the agreement of self-administration and telephone administration of the Timeline Followback interview. Journal of studies on alcohol and drugs, 69(3), 468-71.
  177. Sayers SL, Gordon AJ, Streim JE, Thase M, Sweet R, Haas G, Goldstein (2013). A conceptual framework of comorbidity for investigation in the context of psychiatric disturbance. Current psychiatry reviews, 9(2), 155-63.
  178. Broyles LM, Rodriguez KL, Kraemer KL, Sevick MA, Price PA, Gordon A (2012). A qualitative study of anticipated barriers and facilitators to the implementation of nurse-delivered alcohol screening, brief intervention, and referral to treatment for hospitalized patients in a Veterans Affairs medical center. Addiction science & clinical practice, 7, 7.
  179. Del Re AC, Gordon AJ, Lembke A, Harris A (2013). Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration. Addiction science & clinical practice, 8(1), 12.
  180. Broyles LM, Wieland ME, Confer AL, DiNardo MM, Kraemer KL, Hanusa BH, Youk AO, Gordon AJ, Sevick M (2015). Alcohol brief intervention for hospitalized veterans with hazardous drinking: protocol for a 3-arm randomized controlled efficacy trial. Addiction science & clinical practice, 10, 13.
  181. Bensley KM, McGinnis KA, Fiellin DA, Gordon AJ, Kraemer KL, Bryant KJ, Edelman EJ, Crystal S, Gaither JR, Korthuis PT, Marshall BDL, Ornelas IJ, Chan KCG, Dombrowski JC, Fortney JC, Justice AC, Williams E (2018). Racial/ethnic differences in the association between alcohol use and mortality among men living with HIV. Addiction science & clinical practice, 13(1), 2.
  182. Hagedorn H, Kenny M, Gordon AJ, Ackland PE, Noorbaloochi S, Yu W, Harris AH (2018). Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities. Addiction science & clinical practice, 13(1), 25.
  183. Cochran G, Cole ES, Warwick J, Donohue JM, Gordon AJ, Gellad WF, Bear T, Kelley D, DiDomenico E, Pringle (2019). Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers. Addiction science & clinical practice, 14(1), 25.
  184. Bryan MA, Smid MC, Cheng M, Fortenberry KT, Kenney A, Muniyappa B, Pendergrass D, Gordon AJ, Cochran (2020). Addressing opioid use disorder among rural pregnant and postpartum women: a study protocol. Addiction science & clinical practice, 15(1), 33.
  185. Broyles LM, Kraemer KL, Kengor C, Gordon A (2013). A tailored curriculum of alcohol screening, brief intervention, and referral to treatment (SBIRT) for nurses in inpatient settings. Journal of addictions nursing, 24(3), 130-41.
  186. Broyles LM, Gordon AJ, Rodriguez KL, Hanusa BH, Kengor C, Kraemer K (2013). Evaluation of a pilot training program in alcohol screening, brief intervention, and referral to treatment for nurses in inpatient settings. Journal of addictions nursing, 24(1), 8-19.
  187. Broyles LM, Conley JW, Harding JD Jr, Gordon A (2013). A scoping review of interdisciplinary collaboration in addictions education and training. Journal of addictions nursing, 24(1), 29-36; quiz 37-8.
  188. Jones AL, Hanusa BH, Appelt CJ, Haas GL, Gordon AJ, Hausmann L (2015). Racial Differences in Veterans' Satisfaction With Addiction Treatment Services. Journal of addiction medicine, 9(5), 383-90.
  189. Gordon AJ, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Kelley D, Donohue J (2015). Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program. Journal of addiction medicine, 9(6), 470-7.
  190. Gordon A, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Donohue J (2016). Treatment Quality for Buprenorphine Care: The Pot at the End of the Rainbow. Journal of addiction medicine, 10(3), 210-1.
  191. Andraka-Christou B, Gordon AJ, Bouskill K, Smart R, Randall-Kosich O, Golan M, Totaram R, Stein B (2021). Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes from a Review of State Laws. Journal of addiction medicine,
  192. Cochran G, Cole ES, Sharbaugh M, Nagy D, Gordon AJ, Gellad WF, Pringle J, Bear T, Warwick J, Drake C, Chang CH, DiDomenico E, Kelley D, Donohue (2021). Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder. Journal of addiction medicine, 16(2), e87-e96.
  193. Magel JS, Gordon AJ, Fritz JM, Kim (2021). The Influence of an Opioid Use Disorder on Initiating Physical Therapy for Low Back Pain: A Retrospective Cohort. Journal of addiction medicine, 15(3), 226-232.
  194. Kelley AT, Dungan MT, Gordon A (2020). Barriers and Facilitators to Buprenorphine Prescribing for Opioid Use Disorder in the Veterans Health Administration During COVID-19. Journal of addiction medicine, 15(5), 439-440.
  195. Jones AL, Gelberg L, deRussy AJ, Varley AL, Riggs KR, Gordon AJ, Kertesz S (2020). Low Uptake of Secure Messaging Among Veterans With Experiences of Homelessness and Substance Use Disorders. Journal of addiction medicine, 15(6), 508-511.
  196. Steward J, Holt CL, Pollio DE, Austin EL, Johnson N, Gordon AJ, Kertesz S (2016). Priorities in the primary care of persons experiencing homelessness: convergence and divergence in the views of patients and provider/experts. Patient preference and adherence, 10, 153-8.
  197. Gordon AJ, Geppert CMA, Saxon A, Cotton A, Bondurant T, Krumm M, Acquaviva MP, Trafton (2009). Models for implementing buprenorphine treatment in the VHA. Federal practitioner, 26(5), 48-57.
  198. Gabrielian S, Gordon AJ, Gelberg L, Patel B, Manchanda R, Altman L, Andersen RM, Campell RA, Broyles LM, Conley J, Kertesz (2014). Building primary care medical homes for homeless veterans at 3 VA facilities. Federal practitioner, 31(10), 10-9.
  199. Gabrielian S, Jones AL, Hoge AE, deRussy AJ, Kim YI, Montgomery AE, Blosnich JR, Gordon AJ, Gelberg L, Austin EL, Pollio D, Holmes SK, Varley AL, Kertesz S (2021). Enhancing Primary Care Experiences for Homeless Patients with Serious Mental Illness: Results from a National Survey. Journal of primary care & community health, 12, 2150132721993654.
  200. Stevens ER, Mazumdar M, Caniglia EC, Khan MR, Young KE, Edelman EJ, Gordon AJ, Fiellin DA, Maisto SA, Chichetto NE, Crystal S, Gaither JR, Justice AC, Braithwaite R (2020). Insights Provided by Depression Screening Regarding Pain, Anxiety, and Substance use in a Veteran Population. Journal of primary care & community health, 11, 2150132720949123.
  201. Edelman EJ, Gordon KS, Crothers K, Akgün K, Bryant KJ, Becker WC, Gaither JR, Gibert CL, Gordon AJ, Marshall BDL, Rodriguez-Barradas MC, Samet JH, Justice AC, Tate JP, Fiellin D (2019). Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. JAMA internal medicine, 179(3), 297-304.
  202. Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis (2015). Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. JAMA psychiatry, 72(5), 430-7.
  203. King JT Jr, Perkal MF, Rosenthal RA, Gordon AJ, Crystal S, Rodriguez-Barradas MC, Butt AA, Gibert CL, Rimland D, Simberkoff MS, Justice A (2015). Thirty-day postoperative mortality among individuals with HIV infection receiving antiretroviral therapy and procedure-matched, uninfected comparators. JAMA surgery, 150(4), 343-51.
  204. Badejo OA, Chang CC, So-Armah KA, Tracy RP, Baker JV, Rimland D, Butt AA, Gordon AJ, Rinaldo CR Jr, Kraemer K, Samet JH, Tindle HA, Goetz MB, Rodriguez-Barradas MC, Bedimo R, Gibert CL, Leaf DA, Kuller LH, Deeks SG, Justice AC, Freiberg M (2015). CD8+ T-cells count in acute myocardial infarction in HIV disease in a predominantly male cohort. BioMed research international, 2015, 246870.
  205. Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miro JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Perez-Hoyos S, Jarrin I, Jose S, Sabin C, Hernan M (2015). Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. The lancet. HIV, 2(8), e335-43.
  206. Blosnich JR, Rodriguez KL, Hruska KL, Kavalieratos D, Gordon AJ, Matza A, Mejia SM, Shipherd JC, Kauth M (2019). Utilization of the Veterans Affairs' Transgender E-consultation Program by Health Care Providers: Mixed-Methods Study. JMIR medical informatics, 7(1), e11695.
  207. Cochran G, Lo-Ciganic WH, Gellad WF, Gordon AJ, Cole E, Lobo C, Frazier W, Zheng P, Chang CH, Kelley D, Donohue J (2018). Prescription Opioid Quality Measures Applied Among Pennsylvania Medicaid Enrollees. Journal of managed care & specialty pharmacy, 24(9), 875-885.
  208. Kagabo R, Gordon AJ, Okuyemi (2020). Smoking cessation in inpatient psychiatry treatment facilities: A review. Addictive behaviors reports, 11, 100255.
  209. Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad W (2019). Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. JAMA network open, 2(3), e190968.
  210. Riggs KR, Hoge AE, DeRussy AJ, Montgomery AE, Holmes SK, Austin EL, Pollio DE, Kim YI, Varley AL, Gelberg L, Gabrielian SE, Blosnich JR, Merlin J, Gundlapalli AV, Jones AL, Gordon AJ, Kertesz S (2020). Prevalence of and Risk Factors Associated With Nonfatal Overdose Among Veterans Who Have Experienced Homelessness. JAMA network open, 3(3), e201190.
  211. Gustavson AM, Wisdom JP, Kenny ME, Salameh HA, Ackland PE, Clothier B, Noorbaloochi S, Gordon AJ, Hagedorn H (2021). Early impacts of a multi-faceted implementation strategy to increase use of medication treatments for opioid use disorder in the Veterans Health Administration. Implementation science communications, 2(1), 20.
  212. Mitchell MA, Hedayati DO, Rodriguez KL, True G, Balbale SN, Gordon AJ, Conley JW, Broyles L (2016). Logistical Lessons Learned in Designing and Executing a Photo-Elicitation Study in the Veterans Health Administration.
  213. Gordon A (2006). Screening the drinking: identifying problem alcohol consumption in primary care settings. 6(3), 137-47.
  214. Andraka-Christou B, Golan O, Totaram R, Ohama M, Saloner B, Gordon AJ, Stein B (2023). Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019. Annals of medicine, 55(1), 514-520.
  215. Jones AL, Chu K, Rose DE, Gelberg L, Kertesz SG, Gordon AJ, Wells KB, Leung (2023). Quality of Depression Care for Veterans Affairs Primary Care Patients with Experiences of Homelessness. Journal of general internal medicine,
  216. Charron E, Yu Z, Lundahl B, Silipigni J, Okifuji A, Gordon AJ, Baylis JD, White A, Carlston K, Abdullah W, Haaland B, Krans EE, Smid MC, Cochran (2023). Cluster analysis to identify patient profiles and substance use patterns among pregnant persons with opioid use disorder. Addictive behaviors reports, 17, 100484.
  217. Lott AM, Danner AN, Malte CA, Williams EC, Gordon AJ, Halvorson MA, Saxon AJ, Hagedorn HJ, Sayre GG, Hawkins E (2023). Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation. Journal of addiction medicine,
  218. Bershteyn A, Richard E, Zhou Q, Khan MR, Scheidell JD, Manandhar-Sasaki P, Ban K, Crystal S, Gordon AJ, Justice AC, Bryant KJ, Braithwaite R (2023). Potential health benefits of integrated screening strategies for alcohol, tobacco, other substance use, depression, anxiety, and chronic pain among people living with HIV in the USA: a mathematical modelling study. The lancet. HIV, 10(2), e118-e125.
  219. Stein BD, Landis RK, Sheng F, Saloner B, Gordon AJ, Sorbero M, Dick A (2023). Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention. Journal of general internal medicine, 38(3), 733-737.
  220. Incze MA, Chen D, Galyean P, Kimball ER, Stolebarger L, Zickmund S, Gordon A (2023). Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study. Journal of addiction medicine,
  221. Wyse JJ, Shull S, Lindner S, Morasco BJ, Gordon AJ, Carlson KF, Korthuis PT, Ono SS, Liberto JG, Lovejoy T (2023). Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities. Journal of general internal medicine, 1-6.
  222. Ahrens K, Sharbaugh M, Jarlenski MP, Tang L, Allen L, Austin AE, Barnes AJ, Burns ME, Clark S, Zivin K, Mack A, Liu G, Mohamoud S, McDuffie MJ, Hammerslag L, Gordon AJ, Donohue JM, Writing Committee for MODR (2023). Prevalence of testing for HIV, HBV, and HCV among Medicaid enrollees treated with medications for opioid use disorder in 11 states, 2016-2019. Clinical infectious diseases,
  223. Scheidell JD, Townsend T, Ban KF, Caniglia EC, Charles D, Edelman EJ, Marshall BDL, Gordon AJ, Justice AC, Braithwaite RS, Khan M (2023). Cessation of self-reported opioid use and impacts on co-occurring health conditions. Drug and alcohol dependence, 242, 109712.
  224. Hickey TR, Henry JT, Edens EL, Gordon AJ, Acampora (2023). Perioperative Management of Extended-release Buprenorphine. Journal of addiction medicine, 17(1), e67-e71.
  225. Jones AL, Kelley AT, Suo Y, Baylis JD, Codell NK, West NA, Gordon A (2023). Trends in Health Service Utilization After Enrollment in an Interdisciplinary Primary Care Clinic for Veterans with Addiction, Social Determinants of Health, or Other Vulnerabilities. Journal of general internal medicine, 38(1), 12-20.
  226. Kelley AT, Wilcox J, Baylis JD, Crossnohere NL, Magel J, Jones AL, Gordon AJ, Bridges JF (2022). Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives. Journal of general internal medicine,
  227. Haque LY, Fiellin DA, Tate JP, Esserman D, Bhattacharya D, Butt AA, Crystal S, Edelman EJ, Gordon AJ, Lim JK, Tetrault JM, Williams EC, Bryant K, Cartwright EJ, Rentsch CT, Justice AC, Lo Re V 3rd, McGinnis K (2022). Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA network open, 5(12), e2246604.
  228. Medicaid Outcomes Distributed Research Network (MODRN), Cole ES, Allen L, Austin A, Barnes A, Chang CH, Clark S, Crane D, Cunningham P, Fry CE, Gordon AJ, Hammerslag L, Idala D, Kennedy S, Kim JY, Krishnan S, Lanier P, Mahakalanda S, Mauk R, McDuffie MJ, Mohamoud S, Talbert J, Tang L, Zivin K, Donohue J (2022). Outpatient follow-up and use of medications for opioid use disorder after residential treatment among Medicaid enrollees in 10 states. Drug and alcohol dependence, 241, 109670.
  229. Landis RK, Opper I, Saloner B, Gordon AJ, Leslie DL, Sorbero M, Stein B (2022). Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies. Drug and alcohol dependence, 241, 109669.
  230. Burns M, Tang L, Chang CH, Kim JY, Ahrens K, Allen L, Cunningham P, Gordon AJ, Jarlenski MP, Lanier P, Mauk R, McDuffie MJ, Mohamoud S, Talbert J, Zivin K, Donohue (2022). Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study. Addiction (Abingdon, England), 117(12), 3079-3088.
  231. Landis RK, Levin JS, Saloner B, Gordon AJ, Dick AW, Sherry TB, Leslie DL, Sorbero M, Stein B (2022). Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. Substance abuse, 43(1), 1057-1071.
  232. Riggs KR, DeRussy AJ, Leisch L, Shover CL, Bohnert ASB, Hoge AE, Montgomery AE, Varley AL, Jones AL, Gordon AJ, Kertesz S (2022). Sensitivity of health records for self-reported nonfatal drug and alcohol overdose. The American journal on addictions, 31(6), 517-522.
  233. Varley AL, Hoge A, Riggs KR, deRussy A, Jones AL, Austin EL, Gabrielian S, Gelberg L, Gordon AJ, Blosnich JR, Montgomery AE, Kertesz S (2022). What do Veterans with homeless experience want us to know that we are not asking? A qualitative content analysis of comments from a national survey of healthcare experience. Health & social care in the community, 30(6), e5027-e5037.
  234. Hagedorn HJ, Gustavson AM, Ackland PE, Bangerter A, Bounthavong M, Clothier B, Harris AHS, Kenny ME, Noorbaloochi S, Salameh HA, Gordon A (2022). Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities. Journal of general internal medicine, 37(14), 3594-3602.
  235. Goodman-Meza D, Tang A, Aryanfar B, Vazquez S, Gordon AJ, Goto M, Goetz MB, Shoptaw S, Bui AA (2022). Natural Language Processing and Machine Learning to Identify People Who Inject Drugs in Electronic Health Records. Open forum infectious diseases, 9(9), ofac471.
  236. Smart R, Grant S, Gordon AJ, Pacula RL, Stein B (2022). Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder. JAMA health forum, 3(9), e223285.
  237. Zivin K, Allen L, Barnes AJ, Junker S, Kim JY, Tang L, Kennedy S, Ahrens KA, Burns M, Clark S, Cole E, Crane D, Idala D, Lanier P, Mohamoud S, Jarlenski M, McDuffie MJ, Talbert J, Gordon AJ, Donohue J (2022). Design, Implementation, and Evolution of the Medicaid Outcomes Distributed Research Network (MODRN). Medical care, 60(9), 680-690.
  238. Guo J, Gellad WF, Yang Q, Weiss JC, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Kuza CC, Wilson DL, Lo-Ciganic W (2022). Changes in predicted opioid overdose risk over time in a state Medicaid program: a group-based trajectory modeling analysis. Addiction (Abingdon, England), 117(8), 2254-2263.
  239. Magel J, Bishop MD, Lonnemann E, Cochran G, Fritz JM, West N, Gordon A (2022). The association between advanced orthopedic certification and confidence and engagement in prescription opioid medication misuse management practices: a cross-sectional study. The Journal of manual & manipulative therapy, 30(4), 228-238.
  240. Kraemer KL, Althouse AD, Salay M, Gordon AJ, Wright E, Anisman D, Cochran G, Fischer G, Gellad WF, Hamm M, Kern M, Wasan A (2022). Effect of Different Interventions to Help Primary Care Clinicians Avoid Unsafe Opioid Prescribing in Opioid-Naive Patients With Acute Noncancer Pain: A Cluster Randomized Clinical Trial. JAMA health forum, 3(7), e222263.
  241. Andraka-Christou B, Saloner B, Gordon AJ, Totaram R, Randall-Kosich O, Golan M, Stein B (2022). Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C. The American journal of drug and alcohol abuse, 48(4), 492-503.
  242. Andraka-Christou B, Gordon AJ, Spetz J, Totaram R, Golan M, Randall-Kosich O, Harrison J, Calder S, Kertesz SG, Stein B (2022). Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing. Journal of substance abuse treatment, 138, 108715.
  243. Lo-Ciganic WH, Donohue JM, Yang Q, Huang JL, Chang CY, Weiss JC, Guo J, Zhang HH, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Wilson DL, Kuza CC, Gellad W (2022). Developing and validating a machine-learning algorithm to predict opioid overdose in Medicaid beneficiaries in two US states: a prognostic modelling study. The Lancet. Digital health, 4(6), e455-e465.
  244. Cochran G, Shen J, Cox N, Field C, Carlston K, Sengpraseut B, White A, Okifuji A, Jackman C, Haaland B, Ragsdale R, Gordon AJ, Tarter (2022). Addressing opioid medication misuse at point of service in community pharmacy: A study protocol for an interdisciplinary behavioral health trial. Contemporary clinical trials, 116, 106759.
  245. Perry C, Liberto J, Milliken C, Burden J, Hagedorn H, Atkinson T, McKay JR, Mooney L, Sall J, Sasson C, Saxon A, Spevak C, Gordon AJ, VA/DoD Guideline Development Grou (2022). The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals of internal medicine, 175(5), 720-731.
  246. Stein BD, Saloner B, Kerber R, Sorbero M, Gordon A (2022). Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020. Annals of emergency medicine, 79(5), 441-450.
  247. Incze MA, Kelley AT, Gordon A (2022). Champions Among Us: Leading Primary Care to the Forefront of Opioid Use Disorder Treatment. Journal of general internal medicine, 37(7), 1771-1773.
  248. Andraka-Christou B, Randall-Kosich O, Golan M, Totaram R, Saloner B, Gordon AJ, Stein B (2022). A national survey of state laws regarding medications for opioid use disorder in problem-solving courts. Health & justice, 10(1), 14.
  249. Gordon AJ, Kenny M, Dungan M, Gustavson AM, Kelley AT, Jones AL, Hawkins E, Frank JW, Danner A, Liberto J, Hagedorn (2022). Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings. The American journal on addictions, 31(2), 152-158.
  250. McGinnis KA, Tate JP, Bryant KJ, Justice AC, O'Connor PG, Rodriguez-Barradas MC, Crystal S, Cutter CJ, Hansen NB, Maisto SA, Marconi VC, Williams EC, Cook RL, Gordon AJ, Gordon KS, Eyawo O, Edelman EJ, Fiellin D (2022). Change in Alcohol Use Based on Self-Report and a Quantitative Biomarker, Phosphatidylethanol, in People With HIV. AIDS and behavior, 26(3), 786-794.
  251. Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer K (2022). Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS and behavior, 26(3), 975-985.
  252. Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J, Nuite M, Gordon AJ, Kosten TR, Nunes EV, Rosenheck R, Saxon AJ, Swift R, Goldberg A, Ringer R, Ferguson (2022). Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction science & clinical practice, 17(1), 6.
  253. Williams AR, Johnson KA, Thomas CP, Reif S, Socías ME, Henry BF, Neighbors C, Gordon AJ, Horgan C, Nosyk B, Drexler K, Krawczyk N, Gonsalves GS, Hadland SE, Stein BD, Fishman M, Kelley AT, Pincus HA, Olfson (2022). Opioid use disorder Cascade of care framework design: A roadmap. Substance abuse, 43(1), 1207-1214.
  254. Magel JJ, Cochran G, West N, Fritz JM, Bishop MD, Gordon A (2022). Physical therapists' attitudes are associated with their confidence in and the frequency with which they engage in prescription opioid medication misuse management practices with their patients. A cross-sectional study. Substance abuse, 43(1), 433-441.
  255. White A, Lundahl B, Bryan MA, Okifuji A, Smid M, Gordon AJ, Carlston K, Silipigni J, Abdullah W, Krans EE, Kenney A, Cochran (2022). Pregnancy and the Opioid Crisis: Heightened Effects of COVID-19. Journal of addiction medicine, 16(1), e2-e4.
  256. Hawkins EJ, Malte CA, Gordon AJ, Williams EC, Hagedorn HJ, Drexler K, Blanchard BE, Burden JL, Knoeppel J, Danner AN, Lott A, Liberto JG, Saxon A (2021). Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System. JAMA network open, 4(12), e2137238.
  257. Cabreros I, Griffin BA, Saloner B, Gordon AJ, Kerber R, Stein B (2021). Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories. Drug and alcohol dependence, 228, 109089.
  258. Wyse JJ, Morasco BJ, Dougherty J, Edwards B, Kansagara D, Gordon AJ, Korthuis PT, Tuepker A, Lindner S, Mackey K, Williams B, Herreid-O'Neill A, Paynter R, Lovejoy T (2021). Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence. Drug and alcohol dependence, 228, 108923.
  259. Spelman JF, Edens EL, Maya S, Moore BA, Boggs A, MacLean RR, Ackland P, Becker WC, Lynch D, Garcia-Vassallo M, Burgo AL, Rosen MI, Gordon A (2021). A Facility-Wide Plan to Increase Access to Medication for Opioid Use Disorder in Primary Care and General Mental Health Settings. Federal practitioner, 38(10), 460-464.
  260. Hawkins EJ, Danner AN, Malte CA, Blanchard BE, Williams EC, Hagedorn HJ, Gordon AJ, Drexler K, Burden JL, Knoeppel J, Lott A, Sayre GG, Midboe AM, Saxon A (2021). Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities. Addiction science & clinical practice, 16(1), 55.
  261. Kertesz SG, DeRussy AJ, Riggs KR, Hoge AE, Varley AL, Montgomery AE, Austin EL, Blosnich JR, Jones AL, Gabrielian SE, Gelberg L, Gordon AJ, Richman J (2021). Characteristics Associated With Unsheltered Status Among Veterans. American journal of preventive medicine, 61(3), 357-368.
  262. Gustavson AM, Kenny ME, Wisdom JP, Salameh HA, Ackland PE, Gordon AJ, Hagedorn H (2021). Fluctuations in barriers to medication treatment for opioid use disorder prescribing over the course of a one-year external facilitation intervention. Addiction science & clinical practice, 16(1), 51.
  263. Medicaid Outcomes Distributed Research Network (MODRN), Donohue JM, Jarlenski MP, Kim JY, Tang L, Ahrens K, Allen L, Austin A, Barnes AJ, Burns M, Chang CH, Clark S, Cole E, Crane D, Cunningham P, Idala D, Junker S, Lanier P, Mauk R, McDuffie MJ, Mohamoud S, Pauly N, Sheets L, Talbert J, Zivin K, Gordon AJ, Kennedy (2021). Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018. JAMA, 326(2), 154-164.
  264. Magel J, Kietrys D, Kruger ES, Fritz JM, Gordon A (2021). Physical therapists should play a greater role in managing patients with opioid use and opioid misuse. Substance abuse, 42(3), 255-260.
  265. Joudrey PJ, Bart G, Brooner RK, Brown L, Dickson-Gomez J, Gordon A, Kawasaki SS, Liebschutz JM, Nunes E, McCarty D, Schwartz RP, Szapocnik J, Trivedi M, Tsui JI, Williams A, Wu LT, Fiellin D (2021). Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report. Substance abuse, 42(3), 245-254.
  266. Hayes CJ, Raciborski RA, Martin BC, Gordon AJ, Hudson TJ, Brown CC, Pro G, Cucciare M (2024). Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study. Journal of substance use and addiction treatment, 166, 209461.
  267. Khan MR, Acri M, Ban KF, Scheidell JD, Stevens ER, Manandhar-Sasaki P, Charles D, Chichetto NE, Crystal S, Gordon AJ, Marshall BDL, Edelman EJ, Justice AC, Braithwaite SR, Caniglia E (2024). Associations Between Reductions in Depressive Symptoms and Reductions in Pain and Anxiety Symptoms and Substance Use: Emulation of a Randomized Trial. AJPM focus, 3(5), 100258.
  268. Incze MA, Huebler S, Szczotka K, Grant S, Kertesz SG, Gordon A (2024). Expert Panel Consensus on the Effectiveness and Implementation of Models to Support Posthospitalization Care Transitions for People With Substance Use Disorders. Journal of addiction medicine,
  269. Wyse JJ, Eckhardt A, Newell S, Gordon AJ, Morasco BJ, Carlson K, Korthuis PT, Ono SS, Lovejoy T (2024). Integrating Buprenorphine for Opioid Use Disorder into Rural, Primary Care Settings. Journal of general internal medicine, 39(12), 2142-2149.
  270. Kertesz SG, deRussy AJ, Hoge AE, Varley AL, Holmes SK, Riggs KR, Austin EL, Gordon AJ, Gabrielian SE, Pollio DE, Montgomery AE, Gelberg L, Steward JL, Jones AL, Richman J (2024). Organizational and patient factors associated with positive primary care experiences for veterans with current or recent homelessness. Health services research,
  271. Winhusen TJ, Kropp F, Greenfield SF, Krans EE, Lewis D, Martin PR, Gordon AJ, Davies TH, Wachman EM, Douaihy A, Parker K, Xin X, Jalali A, Lofwall M (2024). Trauma Prevalence and Its Association With Health-Related Quality of Life in Pregnant Persons with Opioid Use Disorder. Journal of addiction medicine,
  272. Magel JS, Beneciuk JM, Siantz E, Fritz J, Garland EL, Hanley A, Shen J, Blosser P, Matev T, Gordon A (2024). PT-IN-MIND: study protocol for a multisite randomised feasibility trial investigating physical therapy with integrated mindfulness (PT-IN-MIND) for patients with chronic musculoskeletal pain and long-term opioid treatment who attend outpatient physical therapy. BMJ open, 14(7), e082611.
  273. Hayes CJ, Martin BC, Hoggatt KJ, Cucciare MA, Hudson TJ, Gordon A (2024). Average Daily Dose Trajectories for Episodes of Buprenorphine Treatment for Opioid Use Disorder. Substance use & addiction journal, 29767342241263161.
  274. Nakamoto CH, Huskamp HA, Donohue JM, Barnett ML, Gordon AJ, Mehrotra (2024). Medicare Payment for Opioid Treatment Programs. JAMA health forum, 5(7), e241907.
  275. Wyse JJ, Mackey K, Kauzlarich KA, Morasco BJ, Carlson KF, Gordon AJ, Korthuis PT, Eckhardt A, Newell S, Ono SS, Lovejoy T (2024). Improving access to buprenorphine for rural veterans in a learning health care system. Health services research,
  276. Incze MA, Huebler S, Grant S, Gordon A (2024). Using the Delphi Process to Prioritize an Agenda for Care Transition Research for Patients With Substance Use Disorders. Substance use & addiction journal, 45(3), 523-528.
  277. Hayes CJ, Bin Noor N, Raciborski RA, Martin BC, Gordon AJ, Hoggatt KJ, Hudson T, Cucciare M (2024). Development and validation of machine-learning algorithms predicting retention, overdoses, and all-cause mortality among US military veterans treated with buprenorphine for opioid use disorder. Journal of addictive diseases, 1-18.
  278. Cooperman NA, Shen J, Gordon AJ, Garland E (2024). Commentary With Study Protocol: Implementation and Effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) as an Adjunct to Methadone Treatment for Opioid Use Disorder (IMPOWR-MORE). Substance use & addiction journal, 29767342241261890.
  279. Schuler MS, Dick AW, Gordon AJ, Saloner B, Kerber R, Stein B (2024). Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018. Drug and alcohol dependence, 259, 111290.
  280. Richardson C, Daniels K, Confer A, Saxon AJ, Gordon AJ, Liberto J, Albanese AP, Renner J, Edens E, Kennedy A (2024). Internal Medicine Resident Addiction Training at the Veteran's Health Administration: A Qualitative Evaluation of Site Directors' Response to the 2022 ACGME Requirements. Journal of general internal medicine, 39(8), 1393-1399.
  281. Eckhardt A, Waller DE, Shull S, Lovejoy TI, Morasco BJ, Gordon AJ, Wyse J (2024). "They Ask Questions, But They Don't Want the Answers"-Perceptions of Clinical Communication Among Veterans Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder. Substance use & addiction journal, 29767342241251761.
  282. Magel J, Siantz E, Blosser P, Fritz JM, Gordon A (2024). The Development of an Opioid Misuse Training Program for Physical Therapists: A Learning Community Approach. Journal, physical therapy education,
  283. Freeman PR, Hammerslag LR, Ahrens KA, Sharbaugh M, Gordon AJ, Austin AE, Donohue JM, Allen LD, Barnes AJ, Talbert J (2024). Barriers to Buprenorphine Dispensing by Medicaid-Participating Community Retail Pharmacies. JAMA health forum, 5(5), e241077.
  284. Wyse JJ, Eckhardt A, Waller D, Gordon AJ, Shull S, Lovejoy TI, Mackey K, Morasco B (2024). Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder. Journal of addiction medicine, 18(3), 300-305.
  285. Hawkins EJ, Malte CA, Hagedorn HJ, Gordon AJ, Williams EC, Trim RS, Blanchard BE, Lott A, Danner AN, Saxon A (2024). Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care. Journal of addiction medicine, 18(3), 240-247.
  286. Hardy CJ, Cochran G, Howey W, Wright E, Wasan AD, Gordon AJ, Kraemer K (2024). Impact of Provider-Facing Interventions to Reduce Opioid Use on Pain Related Outcomes in Primary Care: A Cluster Randomized Trial. Health services research and managerial epidemiology, 11, 23333928241240957.
  287. McCollister KE, Gordon AJ, Acevedo A, Voshtina D, Li JM, Tse B, Murphy S (2024). The 2023 Addiction Health Services Research Conference: Back in Person and Taking a Bite of the Big Apple. Substance use & addiction journal, 45(2), 163-167.
  288. Andraka-Christou B, Golan OK, Williams M, Buksbaum S, Gordon AJ, Stein B (2024). A Systematic Review of State Office-Based Buprenorphine Treatment Laws Effective During 2022: Counseling, Dosage, and Visit Frequency Requirements. Substance use & addiction journal, 45(2), 278-291.
  289. Cox N, Hohmeier KC, Cernasev A, Field C, Elliott S, LaFleur G, Barland KM, Green M, Gardner JW, Gordon AJ, Cochran (2024). Engaging community pharmacies in practice-based research: Lessons from opioid-focused research. Research in social & administrative pharmacy, 20(4), 457-462.
  290. Grant S, Smart R, Gordon AJ, Pacula RL, Stein B (2024). Expert Views on State Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder: A Qualitative Analysis of an Online Modified Delphi Process. Journal of addiction medicine, 18(2), 129-137.
  291. Cochran G, Smid MC, Krans EE, Yu Z, Carlston K, White A, Abdulla W, Baylis J, Charron E, Okifugi A, Gordon AJ, Lundahl B, Silipigni J, Seliski N, Haaland B, Tarter (2024). Patient navigation for pregnant individuals with opioid use disorder: Results of a randomized multi-site pilot trial. Addiction (Abingdon, England), 119(3), 544-556.
  292. Goodman-Meza D, Goto M, Salimian A, Shoptaw S, Bui AAT, Gordon AJ, Goetz M (2024). Impact of Potential Case Misclassification by Administrative Diagnostic Codes on Outcome Assessment of Observational Study for People Who Inject Drugs. Open forum infectious diseases, 11(2), ofae030.
  293. Golan OK, Sheng F, Dick AW, Sorbero M, Whitaker DJ, Andraka-Christou B, Pigott T, Gordon AJ, Stein B (2023). Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009-2018. Drug and alcohol dependence reports, 9, 100193.
  294. Huang LC, Bleicher J, Torre M, Johnson JE, Presson A, Millar MM, Gordon AJ, Brooke BS, Kaphingst KA, Harris AH (2023). Evaluating a health system-wide opioid disposal intervention distributing home-disposal bags. Health services research, 58(6), 1256-1265.
  295. Andraka-Christou B, McAvoy E, Gordon AJ, Ohama M, Brach M, Taylor EA, Vaiana M, Saloner B, Stein B (2023). Urine drug testing in the context of opioid analgesic prescribing for chronic pain: a content analysis of U.S. state laws in 2022. Pain medicine (Malden, Mass.), 24(12), 1306-1317.
  296. Bowman J, Lai M, Charles JE, Gordon AJ, Smid M (2023). Kratom Use Among Pregnant and Lactating Individuals With Substance Use Disorder. Journal of addiction medicine, 17(6), 722-724.
  297. Bridges NC, Taber R, Foulds AL, Bear TM, Cloutier RM, McDonough BL, Gordon AJ, Cochran GT, Donohue JM, Adair D, DiDomenico E, Pringle JL, Gellad WF, Kelley D, Cole E (2023). Medications for opioid use disorder in rural primary care practices: Patient and provider experiences. Journal of substance use and addiction treatment, 154, 209133.
  298. Percy A, Kelley AT, Valentino N, Butz A, Baylis JD, Suo Y, Gordon AJ, Jones A (2023). Care Practices of Mental Health Clinical Pharmacist Practitioners Within an Interdisciplinary Primary Care Model for Patients With Substance Use Disorders. Substance abuse, 44(4), 330-336.
  299. Miller WA, Gordon AJ, Clothier BA, Ackland PE, Bounthavong M, Garcia C, Kenny ME, Noorbaloochi S, Hagedorn H (2023). Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study. Implementation research and practice, 4, 26334895231199463.
  300. Hammerslag L, Talbert J, Donohue JM, Sharbaugh M, Ahrens K, Allen L, Austin AE, Gordon AJ, Jarlenski M, Kim JY, Mohamoud S, Tang L, Burns M, Writing committee for MODR (2023). Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states. Drug and alcohol dependence, 250, 110875.
  301. Ackland PE, Kenny ME, Clothier BA, Salameh HA, Boening N, Gordon AJ, Noorbaloochi S, Gustavson AM, Miller W, Hagedorn H (2023). What Contributes to Sustainability? Examining Access to Medications for Opioid Use Disorder in Low-Adopting VHA Facilities. Journal of general internal medicine, 38(12), 2647-2654.
  302. Garcia CC, Bounthavong M, Gordon AJ, Gustavson AM, Kenny ME, Miller W, Esmaeili A, Ackland PE, Clothier BA, Bangerter A, Noorbaloochi S, Harris AHS, Hagedorn H (2023). Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorder. Implementation science communications, 4(1), 91.
  303. Saloner B, Whitley P, Dawson E, Passik S, Gordon AJ, Stein B (2023). Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. Addiction (Abingdon, England), 118(8), 1549-1556.
  304. Cernasev A, Hohmeier K, Field C, Gordon AJ, Elliott S, Carlston K, Broussard G, Cochran (2023). Co-use of Opioid Medications and Alcohol Prevention Study (COAPS). Substance abuse, 44(3), 130-135.
  305. Lott AM, Danner AN, Malte CA, Williams EC, Gordon AJ, Halvorson MA, Saxon AJ, Hagedorn HJ, Sayre GG, Hawkins E (2023). Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation. Journal of addiction medicine, 17(4), e262-e268.
  306. Incze MA, Chen D, Galyean P, Kimball ER, Stolebarger L, Zickmund S, Gordon A (2023). Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study. Journal of addiction medicine, 17(4), 401-406.
  307. Griffin BA, Cabreros I, Saloner B, Gordon AJ, Kerber R, Stein B (2023). Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads. Substance abuse, 44(3), 136-145.
  308. Schuler MS, Saloner B, Gordon AJ, Dick AW, Stein B (2023). National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018. Substance abuse, 44(3), 154-163.
  309. Gordon AJ, Saxon AJ, Kertesz S, Wyse JJ, Manhapra A, Lin LA, Chen W, Hansen J, Pinnell D, Huynh T, Baylis JD, Cunningham FE, Ghitza UE, Bart G, Yu H, Sauer B (2023). Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug and alcohol dependence, 248, 109902.
  310. Austin AE, Tang L, Kim JY, Allen L, Barnes AJ, Chang CH, Clark S, Cole ES, Durrance CP, Donohue JM, Gordon AJ, Huskamp HA, McDuffie MJ, Mehrotra A, Mohamoud S, Talbert J, Ahrens KA, Applegate M, Hammerslag LR, Lanier P, Tossone K, Zivin K, Burns M (2023). Trends in Use of Medication to Treat Opioid Use Disorder During the COVID-19 Pandemic in 10 State Medicaid Programs. JAMA health forum, 4(6), e231422.
  311. Stein BD, Saloner BK, Golan OK, Andraka-Christou B, Andrews CM, Dick AW, Davis CS, Sheng F, Gordon A (2023). Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment. JAMA health forum, 4(5), e231102.
  312. Charron E, White A, Carlston K, Abdullah W, Baylis JD, Pierce S, Businelle MS, Gordon AJ, Krans EE, Smid MC, Cochran (2023). Prospective acceptability of digital phenotyping among pregnant and parenting people with opioid use disorder: A multisite qualitative study. Frontiers in psychiatry, 14, 1137071.
  313. Cloutier RM, Cole ES, McDonough BL, Lomauro DA, Miller JP, Talbert AL, Bear TM, Bridges NC, Foulds AL, Taber R, Gordon AJ, Cochran GT, Kmiec J, Donohue JM, Kelley D, DiDomenico E, Adair D, Pringle J (2023). Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model. Implementation research and practice, 4, 26334895231152808.
  314. deRussy AJ, Jones AL, Austin EL, Gordon AJ, Gelberg L, Gabrielian SE, Riggs KR, Blosnich JR, Montgomery AE, Holmes SK, Varley AL, Hoge AE, Kertesz S (2023). Insights for Conducting Large-Scale Surveys with Veterans Who Have Experienced Homelessness. Journal of social distress and the homeless, 32(1), 123-134.
  315. Wyse JJ, Lovejoy TI, Gordon AJ, Mackey K, Herreid-O'Neill A, Morasco B (2023). "I'm Clean and Sober, But Not Necessarily Free": Perceptions of Buprenorphine Among Patients in Long-Term Treatment. Substance abuse, 44(1), 41-50.
  316. Magel J, Hartman P, Fritz JM, Koch NN, Dostal H, Vollmer N, Ferguson NL, Tapken J, Cohee K, Cochran G, Gordon A (2023). Patients' Perceptions of Physical Therapists Addressing Opioid Misuse. Substance abuse, 44(1), 32-40.
  317. McCarthy SA, Chinman M, Rogal SS, Klima G, Hausmann LRM, Mor MK, Shah M, Hale JA, Zhang H, Gordon AJ, Gellad W (2022). Tracking the randomized rollout of a Veterans Affairs opioid risk management tool: A multi-method implementation evaluation using the Consolidated Framework for Implementation Research (CFIR). Implementation research and practice, 3, 26334895221114665.
  318. Nock NL, Stoutenberg M, Cook DB, Whitworth JW, Janke EA, Gordon A (2024). Exercise as Medicine for People with a Substance Use Disorder: An ACSM Call to Action Statement. Current sports medicine reports, 23(2), 53-57.
  319. Ackland PE, Kenny ME, Clothier BA, Salameh HA, Boening N, Gordon AJ, Noorbaloochi S, Gustavson AM, Miller W, Hagedorn H (2023). What Contributes to Sustainability? Examining Access to Medications for Opioid Use Disorder in Low-Adopting VHA Facilities. Journal of general internal medicine, 38(12), 2647-2654.
  320. Radmall AO, Calder S, Codell N, Kelley AT, Hawkins E, Jones AL, Hagedorn HJ, Reynolds MA, Gordon A (2022). Roles and Perceptions of Nurses During Implementation of a Medication Treatment for Opioid Use Disorder National Initiative. Journal of addictions nursing, 33(2), 70-79.
  321. Watson R, Morris J, Isitt J, Barrio P, Ortega L, Gual A, Conner K, Stecker T, Maisto S, Paroz S, Graap C, Grazioli VS, Daeppen JB, Collins SE, Bertholet N, McNeely J, Kushnir V, Cunningham JA, Crombie IK, Cunningham KB, Irvine L, Williams B, Sniehotta FF, Norrie J, Melson A, Jones C, Briggs A, Rice P, Achison M, McKenzie A, Dimova E, Slane PW, Grazioli VS, Collins SE, Paroz S, Graap C, Daeppen JB, Baggio S, Dupuis M, Studer J, Gmel G, Magill M, Grazioli VS, Tait RJ, Teoh L, Kelty E, Geelhoed E, Mountain D, Hulse GK, Renko E, Mitchell SG, Lounsbury D, Li Z, Schwartz RP, Gryczynski J, Kirk AS, Oros M, Hosler C, Dusek K, Brown BS, Finnell DS, Holloway A, Wu LT, Subramaniam G, Sharma G, Wallhed Finn S, Andreasson S, Dvorak RD, Kramer MP, Stevenson BL, Sargent EM, Kilwein TM, Harris SK, Sherritt L, Copelas S, Knight JR, The Partnership for Adolescent Substance Use Research, Mdege ND, McCambridge J, Bischof G, Bischof A, Freyer-Adam J, Rumpf HJ, Fitzgerald N, Schölin L, Toner P, Böhnke JR, Veach LJ, Currin O, Dongre LZ, Miller PR, White E, Williams EC, Lapham GT, Bobb JJ, Rubinsky AD, Catz SL, Shortreed S, Bensley KM, Bradley KA, Milward J, Deluca P, Khadjesari Z, Watson R, Fincham-Campbell S, Drummond C, Angus K, Bauld L, Baumann S, Haberecht K, Schnuerer I, Meyer C, Rumpf HJ, John U, Gaertner B, Barrault-Couchouron M, Béracochéa M, Allafort V, Barthélémy V, Bonnefoi H, Bussières E, Garguil V, Auriacombe M, Saint-Jacques M, Dorval M, M'Bailara K, Segura-Garcia L, Ibañez-Martinez N, Mendive-Arbeloa JM, Anoro-Perminger M, Diaz-Gallego P, Piñar-Mateos MªA, Colom-Farran J, Deligianni M, Yersin B, Adam A, Weisner C, Chi F, Lu W, Sterling S, Kraemer KL, McGinnis KA, Fiellin DA, Skanderson M, Gordon AJ, Robbins J, Zickmund S, Korthuis PT, Edelman EJ, Hansen NB, Cutter CJ, Dziura J, Fiellin LE, O'Connor PG, Maisto SA, Bedimo R, Gilbert C, Marconi VC, Rimland D, Rodriguez-Barradas M, Simberkoff M, Justice AC, Bryant KJ, Berman AH, Shorter GW, Bray JW, Barbosa C, Johansson M, Hester R, Campbell W, Souza Formigoni MLO, Andrade ALM, Sartes LMA, Sundström C, Eék N, Kraepelien M, Kaldo V, Fahlke C, Hernandez L, Becker SJ, Jones RN, Graves HR, Spirito A, Diestelkamp S, Wartberg L, Arnaud N, Thomasius R, Gaume J, Grazioli V, Fortini C, Malan Z, Mash B, Everett-Murphy K, Grazioli VS, Studer J, Mohler-Kuo M, Bertholet N, Gmel G, Doi L, Cheyne H, Jepson R, Luna V, Echeverria L, Morales S, Barroso T, Abreu Â, Aguiar C, Stewart D, Abreu A, Brites RM, Jomar R, Marinho G, Parreira P, Seale JP, Johnson JA, Henry D, Chalmers S, Payne F, Tuck L, Morris A, Gonçalves C, Besser B, Casajuana C, López-Pelayo H, Balcells MM, Teixidó L, Miquel L, Colom J, Hepner KA, Hoggatt KJ, Bogart A, Paddock SM, Hardoon SL, Petersen I, Hamilton FL, Nazareth I, White IR, Marston L, Wallace P, Godfrey C, Murray E, Sovinová H, Csémy (2016). Proceedings of the 13th annual conference of INEBRIA. Addiction science & clinical practice, 11(Suppl 1), 13.
  322. Seliski N, Madsen T, Eley S, Colosimo J, Engar T, Gordon A, Barnett C, Humiston G, Morsillo T, Stolebarger L, Smid MC, Cochran (2024). Implementation of a rural emergency department-initiated buprenorphine program in the mountain west: a study protocol. Addiction science & clinical practice, 19(1), 63.
  323. Allen L, Medicaid Outcomes Distributed Research Network (MODRN), Cole E, Sharbaugh M, Austin A, Burns M, Ho Chang CC, Clark S, Crane D, Cunningham P, Durrance C, Fry C, Gordon A, Hammerslag L, Kim JY, Kennedy S, Krishnan S, Mauk R, Talbert J, Tang L, Donohue J (2023). Use of residential opioid use disorder treatment among Medicaid enrollees in nine states. Journal of substance use and addiction treatment, 149, 209034.

Review

  1. Gordon AJ, Sullivan LE, Alford DP, Arnsten JH, Gourevitch MN, Kertesz SG, Kunins HV, Merrill JO, Samet JH, Fiellin D (2007). Update in addiction medicine for the generalist. Journal of general internal medicine, 22(8), 1190-4.
  2. Gordon AJ, Fiellin DA, Friedmann PD, Gourevitch MN, Kraemer KL, Arnsten JH, Saitz (2008). Update in addiction medicine for the primary care clinician. Journal of general internal medicine, 23(12), 2112-6.
  3. Gordon AJ, Kunins HV, Rastegar DA, Tetrault JM, Walley A (2011). Update in addiction medicine for the generalist. Journal of general internal medicine, 26(1), 77-82.
  4. Rastegar DA, Kunins HV, Tetrault JM, Walley AY, Gordon A (2013). 2012 Update in addiction medicine for the generalist. Addiction science & clinical practice, 8, 6.
  5. Gordon AJ, Bertholet N, McNeely J, Starrels JL, Tetrault JM, Walley A (2013). 2013 Update in addiction medicine for the generalist. Addiction science & clinical practice, 8, 18.
  6. Tan CJ, Shufelt T, Behan E, Chantara J, Koomsri C, Gordon AJ, Chaiyakunapruk N, Dhippayom (2023). Comparative effectiveness of psychosocial interventions in adults with harmful use of alcohol: a systematic review and network meta-analysis. Addiction (Abingdon, England),
  7. Kelley AT, Incze MA, Baylis JD, Calder SG, Weiner SJ, Zickmund SL, Jones AL, Vanneman ME, Conroy MB, Gordon AJ, Bridges JF (2022). Patient-centered quality measurement for opioid use disorder: Development of a taxonomy to address gaps in research and practice. Substance abuse, 43(1), 1286-1299.
  8. Wyse JJ, Mackey K, Lovejoy TI, Kansagara D, Tuepker A, Gordon AJ, Todd Korthuis P, Herreid-O'Neill A, Williams B, Morasco B (2022). Expanding access to medications for opioid use disorder through locally-initiated implementation. Addiction science & clinical practice, 17(1), 32.
  9. Incze MA, Kelley AT, James H, Nolan S, Stofko A, Fordham C, Gordon A (2024). Post-hospitalization Care Transition Strategies for Patients with Substance Use Disorders: A Narrative Review and Taxonomy. Journal of general internal medicine, 39(5), 837-846.
  10. Hickey TR, Meeks T, Oxentine H, Park DC, Abelleira A, Edens E, Gordon AJ, Acampora (2023). Perioperative Management of Extended-Release Buprenorphine: A Narrative Review and Case Series. Substance abuse, 44(1), 96-103.

Book

  1. Strain EC (Chair), Gordon AJ, Johnson BA, McCaul ME, Saxon A, Swift R, Zweben (2009). Incorporating Alcohol Pharmacotherapies Into Medical Practice.
  2. Gordon AJ, with contributing authors Gordon JM, Striebel J, Hilton M, Carl K, Maher (2010). Physical Illness and Drugs of Abuse: A Review of the Evidence.

Book Chapter

  1. Gordon AJ, Conigliaro J, Fiellin (2004). Selective methods used in alcohol research: screening in primary care'methods and approaches. 1327-45.
  2. Gordon A (2006). Alcohol and substance abuse in the perioperative period. 231-8.
  3. Gordon AJ, Gordon JM, Broyles L (2013). Medical consequences of unhealthy alcohol use. 107-18.
  4. Gordon AJ, Krumm M (2013). Buprenorphine for opioid dependence. 417-26.
  5. Gordon AJ, Conley JW, Gordon J (2015). Physical diseases and addictive disorders: associations and implications. Vol. 179, 114-28.
  6. Haibach JP, DiNapoli EA, Finnell DS, Kasckow JW, Gordon A (2017). Chapter 15: Motivational Interviewing: its role for the management of mental disorders in primary care.

Editorial

  1. Incze MA, Kelley AT, Gordon A (2021). Improving Opioid Use Disorder Treatment through Quality Assessment. Journal of general internal medicine, 36(9), 2820-2822.
  2. Becker WC, Krebs EE, Edmond SN, Lin LA, Sullivan MD, Weiss RD, Gordon A (2020). A Research Agenda for Advancing Strategies to Improve Opioid Safety: Findings from a VHA State of the Art Conference. Journal of general internal medicine, 35(Suppl 3), 978-982.
  3. Broyles LM, Gordon A (2010). SBIRT implementation: moving beyond the interdisciplinary rhetoric. Substance abuse, 31(4), 221-3.
  4. Gordon AJ, Alford D (2012). Screening, brief intervention, and referral to treatment (SBIRT) curricular innovations: addressing a training gap. Substance abuse, 33(3), 227-30.
  5. Gordon A (2013). Substance abuse journal: new beginnings. Substance abuse, 34(4), 339-41.
  6. Gordon AJ, Broyles L (2014). A physician-centered approach to addiction identification and treatment misses the opportunity for interdisciplinary solutions. Substance abuse, 35(2), 108-9.
  7. Jenkins JA, Gordon A (2014). Advancing the peer review process: a multifaceted approach to improving quality. Substance abuse, 35(2), 105-7.
  8. Gordon A (2014). Maternal and neonatal morbidity: dual harms associated with addiction in pregnancy. Substance abuse, 35(1), 1-2.
  9. Broyles LM, Binswanger IA, Jenkins JA, Finnell DS, Faseru B, Cavaiola A, Pugatch M, Gordon A (2014). Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. Substance abuse, 35(3), 217-21.
  10. Kaminer Y, Gordon A (2014). It is getting late here early: youth substance abuse theory and practice. Substance abuse, 35(4), 329-30.
  11. Jenkins JA, Gordon A (2015). Substance use disorder prevention and treatment in stigmatized patient populations: ripe for innovation. Substance abuse, 36(1), 1-2.
  12. Gordon AJ, Jenkins J (2015). The Time Is Now: The Role of Pharmacotherapies in Expanding Treatment for Opioid Use Disorder. Substance abuse, 36(2), 127-8.
  13. Gordon AJ, Haibach (2015). Screening and Intervening on Alcohol and Other Drug Use in General Wellness Programs: Challenges and Opportunities. Substance abuse, 36(3), 255-6.
  14. Tierney M, Finnell DS, Naegle MA, LaBelle C, Gordon A (2015). Advanced Practice Nurses: Increasing Access to Opioid Treatment by Expanding the Pool of Qualified Buprenorphine Prescribers. Substance abuse, 36(4), 389-92.
  15. Binswanger IA, Gordon A (2016). From risk reduction to implementation: Addressing the opioid epidemic and continued challenges to our field. Substance abuse, 37(1), 1-3.
  16. Gordon A (2016). Integrating policy and research into addiction practice, AMERSA abstracts, and an appreciation to our reviewers. Substance abuse, 37(2), 271-5.
  17. Kaminer Y, Gordon A (2016). The blind side of addiction: A call for increased awareness of developmentally informed youth addiction scholarship. Substance abuse, 37(2), 276-7.
  18. Gordon AJ, Saba S (2016). Confronting the opioid epidemic through publication, promotion, and dissemination of evidence-based addiction scholarship. Substance abuse, 37(3), 379-380.
  19. Frank JW, Wakeman SE, Gordon A (2018). No end to the crisis without an end to the waiver. Substance abuse, 39(3), 263-265.
  20. Gordon AJ, Jenkins JA, Galanter (2015). International addiction scholarship: promise, progress, and results from the annual meeting of the International Society of Addiction Medicine. Substance abuse, 36(2), 129-30.
  21. Jenkins JA, Alford DP, Gordon A (2015). Building connections and bridging interdisciplinary leadership in addictions: 2014 AMERSA annual conference and a thank you to reviewers. Substance abuse, 36(2), 131-4.
  22. Gordon A (2019). AMERSA's 42nd annual meeting: Highlights, abstracts and awards, and an appreciation to our peer reviewers. Substance abuse, 40(1), 2-3.
  23. Gordon A (2019). The International Society of Addiction Medicine (ISAM): Abstracts from its 2018 annual meeting, Busan, Korea. Substance abuse, 40(1), 1.
  24. Cochran G, Bruneau J, Cox N, Gordon A (2020). Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic. Substance abuse, 41(3), 269-274.
  25. Gordon A (2018). Foreword: Ethnographic methods in the study of ethnicity in substance abuse. Journal of ethnicity in substance abuse, 17(1), 1-6.
  26. Hayes CJ, Cucciare MA, Martin BC, Hudson TJ, Bush K, Lo-Ciganic W, Yu H, Charron E, Gordon A (2022). Using data science to improve outcomes for persons with opioid use disorder. Substance abuse, 43(1), 956-963.
  27. Gordon AJ MD, MPH, Oliva E (2018). Applying and advancing best practices in opioid use disorder and addiction treatment: Introduction to the special issue on implementation science and quality improvement scholarship. Substance abuse, 39(2), 125-128.

Letter

  1. Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerda M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BD (2017). Reply to Ruan et al. (2017): Non-medical use of prescription opioids is associated with heroin initiation among US veterans. [Letter to the editor]. Addiction, 112(4), 728-729.
  2. Banerjee G, Edelman EJ, Barry DT, Becker WC, Cerdá M, Crystal S, Gaither JR, Gordon AJ, Gordon KS, Kerns RD, Martins SS, Fiellin DA, Marshall BDL (2017). Reply to Osborne & Serdarevic (2017): Potential impact of exposure definition when examining non-medical use of prescription opioids among US veterans. [Letter to the editor]. Addiction, 112(8), 1510-1511.
  3. Stein BD, Gordon AJ, Dick A (2015). Buprenorphine waivers: the authors reply. Health affairs (Project Hope), 34(8), 1428.
  4. Sowicz TJ, Gordon AJ, Gellad WF, Zhao X, Zhang H, Emmendorfer T, Good C (2018). High Variability of Opioid Prescribing Within and Across Emergency Departments in the US Veterans Health Administration. Journal of general internal medicine, 33(11), 1831-1832.
  5. Bean-Mayberry B, Gordon AJ, Fultz S (2004). The debt repayment paradox for VA clinical investigators. JAMA, 291(19), 2316; author reply 2316.
  6. Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andrée T, McNicholas (2009). Physician training is never a failure. In response and author Comment on Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. The American journal on addictions, 17(4), 337-8.
  7. Gustavson AM, Hagedorn HJ, Jesser LE, Kenny ME, Clothier BA, Bounthavong M, Ackland PE, Gordon AJ, Harris AH (2022). Healthcare quality measures in implementation research: advantages, risks and lessons learned. Health research policy and systems, 20(1), 131.
  8. Kertesz SG, Varley AL, Fuqua LA, Gordon A (2022). The North American opioid crisis: educational failures and incautious stoppage. Lancet (London, England), 400(10361), 1402.

Abstract

  1. Gordon A, Cook R (2003). Drug and alcohol use among HIV-positive (homeless) Veterans [Abstract]. Alcohol Clin Exp Res, 27(5), 187A.
  2. Gordon AJ, Wentz CM, Gibbon JL, Mason AD, Freyder PJ, O'Toole T (1999). Relationships of patient characteristics of successful completion of substance abuse detoxification. Journal of general internal medicine, 14(Suppl 2), 34.
  3. Conigliaro J, McGinnis K, Gordon AJ, Rabeneck L, Briggs J, Justice A (2002). Do providers recognize problem drinking in their HIV-positive patients?. Journal of general internal medicine, 17(Suppl 1), 187.
  4. Kraemer KL, Maisto SA, Conigliaro J, Gordon AJ, McNeil MA, Kelley M (2002). Health services utilization in outpatient drinkers. Journal of general internal medicine, 17(Suppl 1), 200.
  5. Becker W, Edelman EJ, Gordon KS, Kerns R, Crystal S, Fiellin LE, Gordon A, Goulet JL, Justice AC, Fiellin D (2013). Trends and correlates of opioid analgesic receipt among Veterans with and without HIV: 1999-2010. Journal of general internal medicine, 28(1), S227.
  6. Narayanan AK, Saba S, Harding JH, Conley J, Gordon A (2016). Comparing and contrasting US national party platforms: are the two parties more aligned than different regarding official addiction related Advocacy. Addiction in pictures: homeless perspectives of addiction through photo-elicitation. 38(1), suppl 100.
  7. Gordon AJ, Maisto SA, McNeil M, Kraemer KL, Conigliaro RL, Kelley ME, Conigliaro J (2001). Comparison of motivational enhancement and brief advice to decrease elderly hazardous drinking behavior. 22(2), 139.
  8. Kertesz S, Polli D, Holt C, Johnson-Roe K, Gordon A, Steward J, Borden A, Kim T, Stringfellow (2012). Implications of substance abuse for primary care quality of homeless patients. 33(2), 220-1.
  9. Broyles LM, Wieland M, Confer A, Youk, Gordon (2014). Holes in the pipeline: addressing recruitment challenges for an alcohol brief intervention trial in the acute care setting. 35(2), 208.
  10. Cochran G, Gordon AJ, Field C, Bacci J, Dhital R, Ylioja T, Stitzer M, Kelly T, Tarter (2016). A continuum of care model for opioid misuse in community pharmacy. In: Gordon AJ. Integrating Policy and Research into Addiction Practice, AMERSA Abstracts, and an Appreciation to Our Reviewers. 37(2), 271-5 (47A).

Newspaper

  1. Gordon A (2009). Promote treatment. [Letter to the Editor]. 16.
  2. Gordon A (2007). No exceptions. [Letter to the Editor]. B-6.
  3. Gordon A (2008). The liability insurance issue threatens access to care. [Letter to the Editor]. B-6.

Other

  1. Garets M, Archer S, Kitchens C, Cochran G, Gordon A (2019). The 2019 addiction health services research conference: Insights, review, and abstracts. Substance abuse, 40(4), 469-472.
  2. Gordon A (2006). Patients' perspectives on disclosing medical errors. 29(7), 5-9.
  3. Gordon A (2006). Fueling the fire for change: research explores the implications of work hour regulations on graduate medical education. 29(9), 1-8.
  4. Gordon A (2006). Inequity among us: salaries of internists differ based on race and gender. 29(11), 4.
  5. Gordon A (2005). Is your doctor watching your weight?. 28(12), 1-9.
  6. Montlack ML, Gordon AJ, Williams (2005). Integration of services in homeless health care. 94(8), 392-5.
  7. Gaglia MA Jr, Gordon A (2005). For the birds: pandemic influenza policy falls short. 94(12), 606-7.
  8. Gordon A (2006). Buprenorphine: a novel medication in novel environments to treat opioid dependence. 2-5.
  9. Gordon A (2006). Balloons and stamp bags: new possibilities for opioid dependence treatment. 7-8.
  10. Gordon A (2006). Assessing pain: practice outcomes before and after a system intervention. 29(6), 5.
  11. Gordon A (2000). Exploration of alternative treatment settings of alcohol detoxification. [Master's Thesis].
  12. Gordon A (2004). Never "clear" anyone for surgery: the role of medical consultation. 93(8), 403-9.
  13. Montlack M, Gordon A (2004). Too much nog? recommendations for safe drinking this holiday season. 93(11), 552-5.
  14. Gordon A (2004). Improving patient safety: the physician pinch. 93(11), 528-31.
  15. Gordon A (2005). Attitudes toward race and ethnicity data collection. 28(10), 7.
  16. Gordon A (2005). Interpreters, language concordant clinicians, and health care quality. 28(11), 7.
  17. Gordon A (2008). How things change: a reflection of JGIM 10 years ago. 31(1), 2-14.
  18. Gordon AJ, Salmon-Cox (2004). Treatment for opiate addiction in outpatient settings. 92(5), 228-31.
  19. Gordon A (2003). Shape your future: going beyond the patient-physician relationship. 92(4), 187-9.
  20. Gordon A (2007). Chronic benzodiazepine use: evaluating impact on the elderly. 30(8), 6.
  21. Gordon AJ, Conroy M (2007). Japanese medicine: a contrast to Pittsburgh's medical environment. 96(4), 174-7.
  22. Gordon A (2007). Life chaos: impacts on health and health care utilization. 30(9), 2-13.
  23. Gordon A (2007). Modeling the way: time to train physician leaders. 96(11), 496-7.
  24. Gordon A (2006). Tickling the keyboard: older adults and the Internet. 29(12), 6-9.
  25. Gordon A (2006). Alcohol and drug use in women: important HIV risks. 9-10.
  26. Walbrown MA, Gordon A (2006). Treating alcohol drinking: new medications to curb consumption. 95(1), 24-7.
  27. Gordon A (2006). The new bottom line: money not patients. 95(4), 170-1.
  28. Gordon A (2006). Integrating mental health into primary care: innovation and application. 29(1), 4-10.
  29. Gordon A (2006). Promotion of clinical educators and investigators in academic medicine. 29(2), 4-9.
  30. Gordon A (2006). ACLS skills: evaluating residents' performance through simulated scenarios. 29(3), 5-9.
  31. Gordon A (2007). Big Brother is watching us: computers impact doctor-patient interactions. 30(1), 7-13.
  32. Gordon A (2007). A purulent presentation of Proteus pericarditis in Pittsburgh. 30(2), 12.
  33. Gordon A (2008). Inside to outside: enabling and advocating leadership in our ever hostile environments. 97(1), 10-11.
  34. Conroy M, Gordon (2008). More than pierogies: Pittsburgh is perfect for SGIM. 31(3), 5-6.
  35. Gordon A (2008). Translating research into practice: comments of recent JGIM authors. 31(3), 10-12.
  36. Gordon A (2008). Make way for collaboration, integration and respect. 1-16.
  37. Gordon A (2008). It's midnight: do you know where your doctor is?. 97(4), 166-7.
  38. Gordon A (2008). Transparency of health care costs would benefit patients. 4.
  39. Gordon A (2008). What is our message and who is listening?. 97(2), 64-5.
  40. Paidisetty S, Gordon A (2008). Emerging medications to treat alcohol use disorders. 10-13.
  41. Gordon A (2008). I'll write a non-peer-reviewed article any day. 31(6), 2-13.
  42. Gordon A (2008). Research: it's not a dirty word. 97(7), 268-9.
  43. Gordon A (2008). Click. 97(8), 362-98.
  44. Gordon A (2008). The Allegheny County Medical Society: where we have been is not where are we are going. 8.
  45. Gordon A (2008). Looking forward - thinking about the past. 97(9), 408-9.
  46. Gordon A (2008). Click. 31(10), 4-12.
  47. Gordon A (2008). Staying alive ¿ physicians must take care of patients and business. 63(7), 10-11.
  48. Gordon A (2008). Health care crisis: understand, advocate, vote. 31(10), 458-9.
  49. Gordon A (2008). Change and charge: reflections of the year. 97(12), 552-3.
  50. Gordon A (2009). Clinical advocates: where are they? how can we get more?. 32(2), 2-11.
  51. Gordon A (2009). Don't say Gesundheit! when someone says SBIRT!. 98(7), 316-7.
  52. Gunderson EW, Gordon A (2011). Buprenorphine maintenance: effective care delivery in office practice. 9(1), 30-1.
  53. Gordon A, Kertesz S, Phillips (2011). Things you should know about buprenorphine and methadone. 34(6), 7-15.
  54. Gordon A (2013). What not to wear: white coats (aka the coffee splotched infectious vector). 103(6), 244-5.

Report

  1. Goodman F, Gordon A, Kivlahan D, Dalack G, McNicholas L, Oslin D, Saxon A, Suchinsky R, for the VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Pane (2009). Criteria for Use of Buprenorphine/Naloxone and Buprenorphine Sublingual Tablets.
  2. VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives, Gordon A, Kivlahan D, Liberto J, McNicholas L, Oslin D, Saxon A, Trafton (2013). Criteria for Use of Buprenorphine/Naloxone and Buprenorphine Sublingual Tablets.
  3. Donohue JM, Lo-Ciganic Wei-Hsuan, Cochran G, Gordon AJ, Zemaitis MA, Gellad W (2013). Preliminary report on opioid use, opioid use disorder and buprenorphine use in Pennsylvania Medicaid.
  4. Goodman F, Gordon A, Kivlahan D, Dalack G, Pope J, McNicholas L, Suchinsky R, Veterans Health Administration Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Pane (2003). Criteria for Non-formulary Use of Buprenorphine Sublingual Tablets for Opioid Dependence.

Video/Film/CD/Web/Podcast

  1. Olstein J, Gordon AJ, Conigliaro (2011). Identification and management of alcohol use disorders in the perioperative period.
  2. The Management of Substance Use Disorders Working Grou (2009). VA/DoD Clinical Practice Guideline for Management of Substance Use Disorders [Version 2.0 ¿ 2009].
  3. Gordon A (2010). PCSS-B Guidance: The Off-label Use of Sublingual Buprenorphine and Buprenorphine/naloxone for Pain.
  4. The Management of Substance Use Disorders Working Grou (2015). VA/DoD Clinical Practice Guideline for Management of Substance Use Disorders [Version 3.0].
  5. Comer S, Cunningham C, Fishman MJ, Gordon AJ, Kampman K, Langleben D, Nordstrom B, Oslin D, Woody G, Wright T, Wyatt (2015). The National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use.
  6. Gordon A (2008). Dependence vs. Pain. [Commentary].
  7. Gordon A (2009). Models of Care and Office Management of Buprenorphine for the Treatment of Opioid Dependence.